Our research programs focus on the immune system and its pathologies and regroup most investigators involved in this field on the Bordeaux campus.

The immune system is dedicated to preserve the host integrity. When the latter is threatened by environmental pathogens or by abnormal cell growth or stresses, different natural defenses are mobilized to maintain a steady state. However, infectious micro-organisms have evolved adaptive strategies to evade from this immune response. Similarly, cancer development results in part from tumor-induced immunosuppression and immune escape. Conversely, in the case of auto-immune diseases, the immune system itself is dysfunctional and overactivated in relation with yet unknown genetic and/or environmental causes. In organ or stem cell transplantation, uncontrolled immune activation leads to tissue damage or graft rejection. In all these situations, T lymphocytes are key elements to either maintain integrity through effector or regulatory functions, or to enhance pathogenicity.
Consequently, modulation of T cell activation is a general concern in the prevention or cure of various diseases including cancer, infections, autoimmune disorders, graft rejection or graft-versus-host disease. The delineation of the mechanisms underlying this activation is a prerequisite towards this goal. In this context, the global objective of our team since several years is to understand the cellular and molecular mechanisms of human T lymphocyte activation in normal or pathological conditions. A special focus is made on gamma-delta T lymphocytes, on autoimmune diseases and cancer two topics on which our members have developed an expertise, important tools and national and international collaborations since many years.
Our research aims to shed light on the question of how an immune response against foreign or self-antigens can lead to either protective immunity (against CMV or tumors or in surveillance of cell stress), to control of homeostasis (surveillance of tissue integrity) or to breakdown of tolerance (in autoimmunity or transplantation). Imental for optimal development of our studies.

PUBLICATIONS

1              Bailly, E. et al. An extension of the RITUX-ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation. Transplant International 33, 786-795, doi:10.1111/tri.13613 (2020).

2              Barger, D. et al. Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohort’s QuAliV ancillary study. Health and Quality of Life Outcomes 18, doi:10.1186/s12955-020-01451-8 (2020).

3              Baron, F. et al. Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin. Haematologica 105, 1138-1146, doi:10.3324/haematol.2019.227603 (2020).

4              Bazarbachi, A. et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP-EBMT study. British Journal of Haematology 188, 745-756, doi:10.1111/bjh.16182 (2020).

5              Beneteau, M., Daburon, S., Moreau, J. F., Taupin, J. L. & Legembre, P. Erratum: Dominant-negative fas mutation is reversed by down-expression of c-FLIP (Cancer Research (2007) 67 (108–115) DOI: 10.1158/0008-5472.CAN-06-1415). Cancer Research 80, 363, doi:10.1158/0008-5472.CAN-19-3174 (2020).

6              Blaison, F. et al. Cocaïne et lésions destructrices centro-faciales : à propos d’un cas. Revue de Medecine Interne, doi:10.1016/j.revmed.2020.04.010 (2020).

7              Bonnet, M., Visentin, J., Caillat-Zucman, S., Jollet, I. & Taupin, J. L. Monoclonal secondary reagents do not outperform polyclonal secondary reagents for detection of anti-HLA IgG using single antigen flow beads assays. HLA, doi:10.1111/tan.13972 (2020).

8              Brilland, B. et al. Platelets and IgE: Shaping the Innate Immune Response in Systemic Lupus Erythematosus. Clinical Reviews in Allergy and Immunology 58, 194-212, doi:10.1007/s12016-019-08744-x (2020).

9              Brissot, E. et al. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. Journal of Hematology and Oncology 13, doi:10.1186/s13045-020-00923-0 (2020).

10           Calvani, J. et al. In situ multiplex immunofluorescence analysis of the inflammatory burden in kidney allograft rejection: A new tool to characterize the alloimmune response. American Journal of Transplantation 20, 942-953, doi:10.1111/ajt.15699 (2020).

11           Cargou, M., Andreani, M., Battarra, M., Blouin, L. & Visentin, J. Characterization of the novel HLA-DRB3*02:02:23 allele by sequencing-based typing. HLA 95, 150-151, doi:10.1111/tan.13748 (2020).

12           Cargou, M., Andreani, M., Diluzio, A., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DQA1*05:23 allele by sequencing-based typing. HLA 96, 120-121, doi:10.1111/tan.13826 (2020).

13           Cargou, M., Andreani, M., Galluccio, T., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DQA1*03:15 allele by sequencing-based typing. HLA 96, 236-237, doi:10.1111/tan.13950 (2020).

14           Cargou, M., Andreani, M., Galluccio, T., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DRB3*02:142 allele by sequencing-based typing. HLA 95, 581-582, doi:10.1111/tan.13819 (2020).

15           Cargou, M., Andreani, M., Galluccio, T., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DPA1*02:26 allele by sequencing-based typing. HLA 95, 160-161, doi:10.1111/tan.13744 (2020).

16           Cargou, M., Andreani, M., Giustiniani, P., Blouin, L. & Visentin, J. Characterization of the novel HLA-DQA1*05:05:05 allele by sequencing-based typing. HLA, doi:10.1111/tan.13957 (2020).

17           Cargou, M., Andreani, M., Giustiniani, P., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DRB3*03:37 allele by sequencing-based typing. HLA 95, 152-153, doi:10.1111/tan.13750 (2020).

18           Cargou, M., Andreani, M., Locatelli, F., Blouin, L. & Visentin, J. Characterization of the novel HLA-DQA1*01:49 allele by sequencing-based typing. HLA 96, 233-234, doi:10.1111/tan.13949 (2020).

19           Cargou, M., Andreani, M., Locatelli, F., Blouin, L. & Visentin, J. Characterization of the novel HLA-DPA1*01:03:19 allele by sequencing-based typing. HLA 96, 129-130, doi:10.1111/tan.13830 (2020).

20           Cargou, M., Andreani, M., Testa, G., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DQA1*04:08 allele by sequencing-based typing. HLA 95, 584-585, doi:10.1111/tan.13820 (2020).

21           Cargou, M., Andreani, M., Testa, G., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DQA1*01:48 allele by sequencing-based typing. HLA, doi:10.1111/tan.13961 (2020).

22           Cargou, M., Andreani, M., Troiano, M., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DPA1*01:03:16 allele by sequencing-based typing. HLA 95, 158-159, doi:10.1111/tan.13745 (2020).

23           Cargou, M., Andreani, M., Troiano, M., Ralazamahaleo, M. & Visentin, J. Characterization of the novel HLA-DRB3*02:02:25 allele by sequencing-based typing. HLA, doi:10.1111/tan.13945 (2020).

24           Cargou, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DPB1*1089:01 allele by sequencing-based typing. HLA 96, 247-248, doi:10.1111/tan.13951 (2020).

25           Cargou, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-B*27:13:02 allele by sequencing-based typing. HLA 96, 92-93, doi:10.1111/tan.13823 (2020).

26           Cargou, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DRB1*12:82 allele by sequencing-based typing. HLA 95, 147-148, doi:10.1111/tan.13749 (2020).

27           Cargou, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DPB1*04:01:42 allele by sequencing-based typing. HLA 95, 161-163, doi:10.1111/tan.13747 (2020).

28           Cargou, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-A*11:361 allele by sequencing-based typing. HLA, doi:10.1111/tan.13948 (2020).

29           Cargou, M., Elsermans, V., Top, I., Ralazamahaleo, M. & Visentin, J. Characterization of the novel HLA-C*04:408 allele by sequencing-based typing. HLA 96, 101-102, doi:10.1111/tan.13822 (2020).

30           Cargou, M., Elsermans, V., Top, I., Ralazamahaleo, M. & Visentin, J. Characterization of the novel HLA-DQB1*06:361 allele by sequencing-based typing. HLA 96, 125-127, doi:10.1111/tan.13829 (2020).

31           Cargou, M., Elsermans, V., Top, I., Ralazamahaleo, M. & Visentin, J. Characterization of the novel HLA-B*44:192:04 allele by sequencing-based typing. HLA 95, 573-574, doi:10.1111/tan.13818 (2020).

32           Cargou, M., Elsermans, V., Top, I., Ralazamahaleo, M. & Visentin, J. Characterization of the novel HLA-DRB1*15:178 allele by sequencing-based typing. HLA 95, 149-150, doi:10.1111/tan.13746 (2020).

33           Cargou, M., Elsermans, V., Top, I., Ralazamahaleo, M. & Visentin, J. Characterization of the novel HLA-C*03:517 allele by sequencing-based typing. HLA, doi:10.1111/tan.13958 (2020).

34           Cargou, M., Ralazamahaleo, M., Blouin, L., Guidicelli, G. & Visentin, J. Improvement in HLA-C typing by a new sequence-specific oligonucleotides kit. HLA, doi:10.1111/tan.13986 (2020).

35           Cargou, M. et al. Evaluation of the AllType kit for HLA typing using the Ion Torrent S5 XL platform. HLA 95, 30-39, doi:10.1111/tan.13708 (2020).

36           Danielou, M. et al. Natural History of Perianal Fistulising Lesions in Patients with Elderly-onset Crohn’s Disease: A Population-based Study. Journal of Crohn’s and Colitis 14, 501-507, doi:10.1093/ecco-jcc/jjz173 (2020).

37           De Précigout, V. et al. No Improvement of Hepatitis B Vaccination Response in Patients Dialysed with a Polymethylmethacrylate Membrane Compared to High-Flux Polysulfone: Results of the HEPADIAL Study. Blood Purification 49, 265-271, doi:10.1159/000504035 (2020).

38           Debureaux, P. E. et al. FLAG-sequential regimen followed by bone marrow transplantation for myelodysplastic syndrome or acute leukemia in patients with Fanconi anemia: a Franco-Brazilian study. Bone Marrow Transplantation, doi:10.1038/s41409-020-0994-2 (2020).

39           Del Bello, A. et al. Outcome of Liver Transplant Patients With Preformed Donor-Specific Anti–Human Leukocyte Antigen Antibodies. Liver Transplantation 26, 256-267, doi:10.1002/lt.25663 (2020).

40           Domblides, C. et al. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. Journal of Thoracic Oncology 15, 860-866, doi:10.1016/j.jtho.2020.01.014 (2020).

41           Dos Santos Rocha, A. et al. Characteristics and opinions of MD-PhD students and graduates from different European countries: a study from the European MD-PhD Association. Swiss medical weekly 150, w20205, doi:10.4414/smw.2020.20205 (2020).

42           Douglas, T. & Saleh, M. The plot thickens: OTULIN regulation in cell death. Molecular and Cellular Oncology 7, doi:10.1080/23723556.2020.1740541 (2020).

43           Douglas, T. & Saleh, M. Cross-regulation between LUBAC and caspase-1 modulates cell death and inflammation. Journal of Biological Chemistry 295, 5216-5228, doi:10.1074/jbc.RA119.011622 (2020).

44           Dufour, A. M. et al. IL-17A Dissociates Inflammation from Fibrogenesis in Systemic Sclerosis. Journal of Investigative Dermatology 140, 103-112.e108, doi:10.1016/j.jid.2019.05.026 (2020).

45           Elsermans, V., Visentin, J., Top, I., Varlet, P. & Labalette, M. Characterization of the novel HLA-B*27:198 allele by sequencing-based typing. HLA, doi:10.1111/tan.13967 (2020).

46           Elsermans, V., Visentin, J., Top, I., Varlet, P. & Labalette, M. Characterization of the novel HLA-DQB1*02:141 allele by sequencing-based typing. HLA, doi:10.1111/tan.13964 (2020).

47           Elsermans, V., Visentin, J., Top, I., Varlet, P. & Labalette, M. Characterization of the novel HLA-B*18:161 allele by sequencing-based typing. HLA, doi:10.1111/tan.13965 (2020).

48           Elsermans, V., Visentin, J., Top, I., Varlet, P. & Labalette, M. Characterization of the novel HLA-DRB1*04:275 allele by sequencing-based typing. HLA, doi:10.1111/tan.13960 (2020).

49           Espada, E. et al. BK virus–specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Advances 4, 1881-1893, doi:10.1182/bloodadvances.2019001120 (2020).

50           Gatault, P. et al. The FcγRIIIA-158 VV genotype increased the risk of post-transplant lymphoproliferative disorder in T-cell-depleted kidney transplant recipients – a retrospective study. Transplant International 33, 936-947, doi:10.1111/tri.13624 (2020).

51           Gendron, N. et al. Aplastic anemia related to thymoma: a survey on behalf of the French reference center of aplastic anemia and a review of the literature. Haematologica 105, E333-E336, doi:10.3324/haematol.2019.226134 (2020).

52           Geneviève, M. et al. Poor kidney graft survival in anorexia nervosa patients. Eating and Weight Disorders, doi:10.1007/s40519-020-00959-8 (2020).

53           Gensous, N., Bacalini, M. G., Franceschi, C. & Garagnani, P. Down syndrome, accelerated aging and immunosenescence. Seminars in Immunopathology, doi:10.1007/s00281-020-00804-1 (2020).

54           Gensous, N. et al. One-year Mediterranean diet promotes epigenetic rejuvenation with country- and sex-specific effects: a pilot study from the NU-AGE project. GeroScience 42, 687-701, doi:10.1007/s11357-019-00149-0 (2020).

55           Gensous, N. et al. Aging and caloric restriction modulate the dna methylation profile of the ribosomal rna locus in human and rat liver. Nutrients 12, doi:10.3390/nu12020277 (2020).

56           Germain, V., Scherlinger, M., Barnetche, T. & Schaeverbeke, T. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: The weight of nocebo effect. Annals of the Rheumatic Diseases 79, E11, doi:10.1136/annrheumdis-2018-214374 (2020).

57           Gilleece, M. H. et al. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. Leukemia 34, 87-99, doi:10.1038/s41375-019-0527-4 (2020).

58           Gossec, L. et al. Agreement with the French 2019 recommendations on treatment adherence in rheumatic diseases among 357 health professionals. Joint Bone Spine, doi:10.1016/j.jbspin.2020.04.008 (2020).

59           Grange, L., Guilpain, P., Truchetet, M. E., Cracowski, J. L. & Societe francaise de pharmacologie et de, t. Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review. Therapies, doi:10.1016/j.therap.2020.06.013 (2020).

60           Greslehner, G. P. Microbiome Structure and Function: A New Framework for Interpreting Data. BioEssays 42, doi:10.1002/bies.201900255 (2020).

61           Greslehner, G. P. & Lemoine, M. A dual decomposition strategy of both microbial and phenotypic components for a better understanding of causal claims. Biology and Philosophy 35, doi:10.1007/s10539-019-9708-9 (2020).

62           Gross-Goupil, M., Domblides, C., Lefort, F. & Ravaud, A. Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve. Bulletin du Cancer 107, eS1-eS7, doi:10.1016/S0007-4551(20)30280-0 (2020).

63           Guay, A. & Pradeu, T. Right out of the box: how to situate metaphysics of science in relation to other metaphysical approaches. Synthese 197, 1847-1866, doi:10.1007/s11229-017-1576-8 (2020).

64           Hémar, V. et al. Sarcoid Dactylitis. Arthritis and Rheumatology 72, 1038, doi:10.1002/art.41212 (2020).

65           Henrot, P. et al. Decreased CCN3 in Systemic Sclerosis Endothelial Cells Contributes to Impaired Angiogenesis. Journal of Investigative Dermatology 140, 1427-1434.e1425, doi:10.1016/j.jid.2019.11.026 (2020).

66           Henrot, P. et al. Is Hyperpigmentation in Systemic Sclerosis a Perivascular Dermal Tattoo? Journal of Investigative Dermatology, doi:10.1016/j.jid.2020.03.937 (2020).

67           Henrot, P., Pain, C., Taïeb, A., Truchetet, M. E. & Cario, M. Dysregulation of CCN3 (NOV) expression in the epidermis of systemic sclerosis patients with pigmentary changes. Pigment Cell and Melanoma Research, doi:10.1111/pcmr.12912 (2020).

68           Heraudet, L., Domblides, C., Daste, A., Gross-Goupil, M. & Ravaud, A. Adaptation of multidisciplinary meeting decisions in a medical oncology department during the COVID epidemic in a less affected region of France: a prospective analysis from Bordeaux University Hospital. European Journal of Cancer 135, 98-100, doi:10.1016/j.ejca.2020.04.039 (2020).

69           Heraudet, L. et al. Safety of sunitinib in patients with renal cell carcinoma following nephrectomy. Expert Opinion on Drug Safety 19, 799-806, doi:10.1080/14740338.2020.1774551 (2020).

70           Hillion, S. et al. The Innate Part of the Adaptive Immune System. Clinical Reviews in Allergy and Immunology 58, 151-154, doi:10.1007/s12016-019-08740-1 (2020).

71           Injarabian, L. et al. Ascorbate maintains a low plasma oxygen level. Scientific Reports 10, doi:10.1038/s41598-020-67778-w (2020).

72           Kamar, N. et al. A Randomized Prospective Study Comparing Anti–T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients. Kidney International Reports 5, 1207-1217, doi:10.1016/j.ekir.2020.05.020 (2020).

73           Kaminski, H. et al. Effect of mTOR inhibitors during CMV disease in kidney transplant recipients: Results of a pilot retrospective study. Microbiology and Immunology 64, 520-531, doi:10.1111/1348-0421.12794 (2020).

74           Kanda, J. et al. Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. Leukemia 34, 128-137, doi:10.1038/s41375-019-0534-5 (2020).

75           Karunakaran, M. M. et al. Butyrophilin-2A1 Directly Binds Germline-Encoded Regions of the Vγ9Vδ2 TCR and Is Essential for Phosphoantigen Sensing. Immunity 52, 487-498.e486, doi:10.1016/j.immuni.2020.02.014 (2020).

76           Khanna, D. et al. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): Randomised, double-blind, placebo-controlled multicentre trial. Annals of the Rheumatic Diseases 79, 618-625, doi:10.1136/annrheumdis-2019-216823 (2020).

77           Lafon, M. et al. Atezolizumab for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy 20, 679-686, doi:10.1080/14712598.2020.1751113 (2020).

78           Lapoirie, J. et al. Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms. Journal of Maternal-Fetal and Neonatal Medicine 33, 49-56, doi:10.1080/14767058.2018.1484097 (2020).

79           Le Bourgeois, A. et al. Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. Annals of Hematology 99, 1855-1862, doi:10.1007/s00277-020-04074-7 (2020).

80           Le Saos-Patrinos, C., Loizon, S., Blanco, P., Viallard, J. F. & Duluc, D. Functions of Tfh Cells in Common Variable Immunodeficiency. Frontiers in Immunology 11, doi:10.3389/fimmu.2020.00006 (2020).

81           Ledoult, E. et al. Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis. Arthritis Research and Therapy 22, doi:10.1186/s13075-020-2113-6 (2020).

82           Maillet, T. et al. Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. Journal of Autoimmunity 106, doi:10.1016/j.jaut.2019.102338 (2020).

83           Mamez, A. C. et al. Allogeneic stem cell transplantation for peripheral T cell lymphomas: A retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Journal of Hematology and Oncology 13, doi:10.1186/s13045-020-00892-4 (2020).

84           Massara, L. et al. Uncovering the Anticancer Potential of Murine Cytomegalovirus against Human Colon Cancer Cells. Molecular Therapy – Oncolytics 16, 250-261, doi:10.1016/j.omto.2020.01.007 (2020).

85           Mattuizzi, A. et al. Obstetrics complications of systemic lupus erythematosus and antiphospholipid syndrome: A multidisciplinary management. Gynecologie Obstetrique Fertilite et Senologie 48, 448-452, doi:10.1016/j.gofs.2020.03.005 (2020).

86           Mattuizzi, A. et al. Adverse perinatal outcomes of chronic intervillositis of unknown etiology: an observational retrospective study of 122 cases. Scientific Reports 10, doi:10.1038/s41598-020-69191-9 (2020).

87           Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. New England Journal of Medicine 382, 211-221, doi:10.1056/NEJMoa1912196 (2020).

88           Noël, N. et al. Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in France. Autoimmunity Reviews 19, doi:10.1016/j.autrev.2020.102464 (2020).

89           Passweg, J. R. et al. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Biology of Blood and Marrow Transplantation 26, 659-664, doi:10.1016/j.bbmt.2019.11.021 (2020).

90           Pernin, V. et al. Distribution of de novo Donor-Specific Antibody Subclasses Quantified by Mass Spectrometry: High IgG3 Proportion Is Associated With Antibody-Mediated Rejection Occurrence and Severity. Frontiers in Immunology 11, doi:10.3389/fimmu.2020.00919 (2020).

91           Poiré, X. et al. Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: A study from the Acute Leukemia Working Party of the EBMT. Haematologica 105, 414-423, doi:10.3324/haematol.2019.216168 (2020).

92           Poiré, X. et al. The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. American Journal of Hematology 95, 282-294, doi:10.1002/ajh.25714 (2020).

93           Richez, C. et al. Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. Joint Bone Spine, doi:10.1016/j.jbspin.2020.05.006 (2020).

94           Richez, C., Lazaro, E., Lemoine, M., Truchetet, M. E. & Schaeverbeke, T. Implications du COVID-19 pour la prise en charge des rhumatismes inflammatoires chroniques. Revue du Rhumatisme (Edition Francaise) 87, 143-145, doi:10.1016/j.rhum.2020.03.008 (2020).

95           Richez, C., Lazaro, E., Lemoine, M., Truchetet, M. E. & Schaeverbeke, T. Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases. Joint Bone Spine 87, 187-189, doi:10.1016/j.jbspin.2020.03.010 (2020).

96           Richez, C. & Truchetet, M. E. What value do JAK inhibitors have in treating rheumatoid arthritis? Expert Opinion on Pharmacotherapy, doi:10.1080/14656566.2020.1779703 (2020).

97           Santos, M. E. et al. HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort). AIDS and Behavior 24, 1069-1084, doi:10.1007/s10461-019-02585-7 (2020).

98           Scherlinger, M. et al. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. Autoimmunity Reviews 19, doi:10.1016/j.autrev.2020.102531 (2020).

99           Scherlinger, M. & Schaeverbeke, T. To switch or not to switch’: The missing piece in the puzzle of biosimilar literature? Annals of the Rheumatic Diseases 79, doi:10.1136/annrheumdis-2018-214908 (2020).

100         Schmaelter, A. K. et al. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer Journal 10, doi:10.1038/s41408-020-0296-3 (2020).

101         Sebestyen, Z., Prinz, I., Déchanet-Merville, J., Silva-Santos, B. & Kuball, J. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies. Nature Reviews Drug Discovery 19, 169-184, doi:10.1038/s41573-019-0038-z (2020).

102         Shouval, R. et al. Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. Bone Marrow Transplantation, doi:10.1038/s41409-020-0936-z (2020).

103         Soni, C. et al. Plasmacytoid Dendritic Cells and Type I Interferon Promote Extrafollicular B Cell Responses to Extracellular Self-DNA. Immunity 52, 1022-1038.e1027, doi:10.1016/j.immuni.2020.04.015 (2020).

104         Tang, M. A. H. et al. Prognostic factor of poor outcome in anti-MAG neuropathy: clinical and electrophysiological analysis of a French Cohort. Journal of Neurology 267, 561-571, doi:10.1007/s00415-019-09618-0 (2020).

105         Vial, G. et al. Factors influencing the choice of biologic therapy following Rituximab in patients with rheumatoid arthritis: A retrospective study using propensity score. Joint Bone Spine 87, 43-48, doi:10.1016/j.jbspin.2019.07.008 (2020).

106         Villeneuve, C. et al. Adherence profiles in kidney transplant patients: Causes and consequences. Patient Education and Counseling 103, 189-198, doi:10.1016/j.pec.2019.08.002 (2020).

107         Visentin, J. et al. Reassessment of the clinical impact of preformed donor-specific anti-HLA-Cw antibodies in kidney transplantation. American Journal of Transplantation 20, 1365-1374, doi:10.1111/ajt.15766 (2020).

108         Zuber, J. et al. Donor-targeted serotherapy as a rescue therapy for steroid-resistant acute GVHD after HLA-mismatched kidney transplantation. American Journal of Transplantation 20, 2243-2253, doi:10.1111/ajt.15827 (2020).

1              Audemard-Verger, A. et al. Recruitment of CXCR3 + T cells into injured tissues in adult IgA vasculitis patients correlates with disease activity. Journal of Autoimmunity 99, 73-80, doi:10.1016/j.jaut.2019.01.012 (2019).

2              Bacalini, M. G. et al. Molecular aging of human liver: An epigenetic/transcriptomic signature. Journals of Gerontology – Series A Biological Sciences and Medical Sciences 74, 1-8, doi:10.1093/gerona/gly048 (2019).

3              Balligand, L. et al. Single-Unit versus Double-Unit Umbilical Cord Blood Transplantation in Children and Young Adults with Residual Leukemic Disease. Biology of Blood and Marrow Transplantation 25, 734-742, doi:10.1016/j.bbmt.2018.10.016 (2019).

4              Baron, F. et al. Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. Blood Cancer Journal 9, doi:10.1038/s41408-019-0204-x (2019).

5              Bazarbachi, A. et al. Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: A report of the EBMT Acute Leukemia Working Party. Haematologica 104, E398-E401, doi:10.3324/haematol.2018.211615 (2019).

6              Ben Hassine, I. et al. Osseous sarcoidosis: A multicenter retrospective case-control study of 48 patients. Joint Bone Spine 86, 789-793, doi:10.1016/j.jbspin.2019.07.009 (2019).

7              Bich, L., Pradeu, T. & Moreau, J. F. Understanding Multicellularity: The Functional Organization of the Intercellular Space. Frontiers in Physiology 10, doi:10.3389/fphys.2019.01170 (2019).

8              Blouin, L., Andreani, M., Battarra, M., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DRB3*02:96 allele by sequencing-based typing. HLA 94, 464-465, doi:10.1111/tan.13653 (2019).

9              Blouin, L., Andreani, M., Locatelli, F., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DPA1*02:15 allele by sequencing-based typing. HLA 94, 179-180, doi:10.1111/tan.13573 (2019).

10           Boulon, C. et al. Correlation between capillaroscopic classifications and severity in systemic sclerosis: results from SCLEROCAP study at inclusion. Clinical and experimental rheumatology 37, 63-68 (2019).

11           Boyer, A. et al. Tailoring empirical antimicrobial therapy in subjects with ventilator-associated pneumonia with a 10-hour E-test approach. Respiratory Care 64, 307-312, doi:10.4187/respcare.06255 (2019).

12           Canaani, J. et al. Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. Leukemia 33, 1944-1952, doi:10.1038/s41375-019-0439-3 (2019).

13           Cargou, M., Andreani, M., Battarra, M., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DRB3*02:02:17 allele by sequencing-based typing. HLA 94, 170-171, doi:10.1111/tan.13566 (2019).

14           Cargou, M., Andreani, M., Battarra, M., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-C*07:708 allele by sequencing-based typing. HLA 93, 235-236, doi:10.1111/tan.13479 (2019).

15           Cargou, M., Andreani, M., Testa, G., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DPA1*01:20 allele by sequencing-based typing. HLA 94, 396-397, doi:10.1111/tan.13648 (2019).

16           Cargou, M., Andreani, M., Troiano, M., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DQA1*05:14 allele by sequencing-based typing. HLA 93, 241-243, doi:10.1111/tan.13484 (2019).

17           Cargou, M., Andreani, M., Troiano, M., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DQA1*01:22 allele by sequencing-based typing. HLA 94, 333-334, doi:10.1111/tan.13577 (2019).

18           Cargou, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-A*03:350 allele by sequencing-based typing. HLA 94, 154-155, doi:10.1111/tan.13567 (2019).

19           Cargou, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DRB1*01:100 allele by sequencing-based typing. HLA 94, 166-167, doi:10.1111/tan.13572 (2019).

20           Cargou, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-A*11:324 allele by sequencing-based typing. HLA 94, 155-156, doi:10.1111/tan.13561 (2019).

21           Cargou, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DPB1*896:01 allele by sequencing-based typing. HLA 93, 246-247, doi:10.1111/tan.13485 (2019).

22           Cargou, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-A*33:170 allele by sequencing-based typing. HLA 93, 221-223, doi:10.1111/tan.13480 (2019).

23           Cargou, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-A*03:315 allele by sequencing-based typing. HLA 93, 39-40, doi:10.1111/tan.13420 (2019).

24           Cargou, M., Ralazamahaleo, M., Blouin, L., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DQA1*04:05 allele by sequencing-based typing. HLA 93, 59-60, doi:10.1111/tan.13431 (2019).

25           Cargou, M., Ralazamahaleo, M., Blouin, L., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DRB5*02:21 allele by sequencing-based typing. HLA 93, 58-59, doi:10.1111/tan.13417 (2019).

26           Cargou, M., Ralazamahaleo, M., Blouin, L., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-A*30:135 allele by sequencing-based typing. HLA 93, 46-47, doi:10.1111/tan.13421 (2019).

27           Cargou, M., Ralazamahaleo, M., Blouin, L., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DPA1*02:12 allele by sequencing-based typing. HLA 93, 61-62, doi:10.1111/tan.13418 (2019).

28           Chasset, F. et al. Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers). Joint Bone Spine 86, 165-171, doi:10.1016/j.jbspin.2018.10.007 (2019).

29           Costedoat-Chalumeau, N. et al. A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clinical Pharmacology and Therapeutics 106, 374-382, doi:10.1002/cpt.1194 (2019).

30           Daien, C. et al. Update of French society for rheumatology recommendations for managing rheumatoid arthritis. Joint Bone Spine 86, 135-150, doi:10.1016/j.jbspin.2018.10.002 (2019).

31           Daste, A., Digue, L., Ravaud, A. & Domblides, C. Dramatic response under combination of immune-oncology in head & neck cancer included in the Condor study: A case report. Oral Oncology 89, 150-152, doi:10.1016/j.oraloncology.2019.01.002 (2019).

32           Dauchy, F. A. et al. Trypanosoma brucei gambiense excreted/secreted factors impair lipopolysaccharide-induced maturation and activation of human monocyte-derived dendritic cells. Parasite Immunology 41, doi:10.1111/pim.12632 (2019).

33           Delaval, L. et al. Large-vessel vasculitis diagnosed between 50 and 60 years: Case-control study based on 183 cases and 183 controls aged over 60 years. Autoimmunity Reviews 18, 714-720, doi:10.1016/j.autrev.2019.05.008 (2019).

34           Delville, M. et al. Early acute microvascular kidney transplant rejection in the absence of anti-HLA antibodies is associated with preformed IgG antibodies against diverse glomerular endothelial cell antigens. Journal of the American Society of Nephrology 30, 692-709, doi:10.1681/ASN.2018080868 (2019).

35           Di Lorenzo, B. et al. Broad cytotoxic targeting of acute myeloid leukemia by polyclonal delta one T cells. Cancer Immunology Research 7, 552-558, doi:10.1158/2326-6066.CIR-18-0647 (2019).

36           Douglas, T. & Saleh, M. Post-translational Modification of OTULIN Regulates Ubiquitin Dynamics and Cell Death. Cell Reports 29, 3652-3663.e3655, doi:10.1016/j.celrep.2019.11.014 (2019).

37           Ducours, M. et al. Starry erythema under bortezomib. Presse Medicale 48, 1187-1189, doi:10.1016/j.lpm.2019.09.007 (2019).

38           Dumas, P. Y. et al. Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission. Cancer Medicine 8, 4976-4985, doi:10.1002/cam4.2371 (2019).

39           Durand, P. et al. Complete remission of immune thrombocytopenia in a 30-year old woman after excision of a right atrial myxoma. British Journal of Haematology 187, e18-e19, doi:10.1111/bjh.16135 (2019).

40           Durel, C. A. et al. Orbital mass in ANCA-associated vasculitides: Data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. Rheumatology (United Kingdom) 58, 1565-1573, doi:10.1093/rheumatology/kez071 (2019).

41           Duricova, D. et al. Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn′s Disease: A French Population-Based Study. Inflammatory Bowel Diseases 25, 394-402, doi:10.1093/ibd/izy254 (2019).

42           Elhai, M. et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: A prospective cohort study. Annals of the Rheumatic Diseases 78, 979-987, doi:10.1136/annrheumdis-2018-214816 (2019).

43           Elsermans, V., Visentin, J., Top, I., Labalette, M. & Varlet, P. Characterization of the novel HLA-DRB1*13:191 allele by sequencing-based typing. HLA 93, 55-56, doi:10.1111/tan.13452 (2019).

44           Elsermans, V., Visentin, J., Top, I., Varlet, P. & Labalette, M. Characterization of the novel HLA-C*07:724 allele by sequencing-based typing. HLA 94, 77-78, doi:10.1111/tan.13546 (2019).

45           Elsermans, V., Visentin, J., Top, I., Varlet, P. & Labalette, M. Characterization of the novel HLA-B*07:02:73 allele by sequencing-based typing. HLA 94, 65-66, doi:10.1111/tan.13545 (2019).

46           Elsermans, V., Visentin, J., Top, I., Varlet, P. & Labalette, M. Characterization of the novel HLA-DQB1*03:353 allele by sequencing-based typing. HLA 94, 86-87, doi:10.1111/tan.13540 (2019).

47           Elsermans, V., Visentin, J., Top, I., Varlet, P. & Labalette, M. Characterization of the novel HLA-DRB1*14:207 allele by sequencing-based typing. HLA 94, 85-86, doi:10.1111/tan.13539 (2019).

48           Elsermans, V., Visentin, J., Top, I., Varlet, P. & Labalette, M. Characterization of the novel HLA-C*03:302 allele by sequencing-based typing. HLA 93, 51-52, doi:10.1111/tan.13445 (2019).

49           Forcade, E. et al. Clinical pharmacy in a bone marrow and cellular therapy transplantation ward–which methods to put in place: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC). Bulletin du Cancer 106, S59-S70, doi:10.1016/j.bulcan.2018.07.020 (2019).

50           Franceschi, C. et al. Accelerated bio-cognitive aging in Down syndrome: State of the art and possible deceleration strategies. Aging Cell 18, doi:10.1111/acel.12903 (2019).

51           Gaillard, F. et al. Impact of estimation versus direct measurement of predonation glomerular filtration rate on the eligibility of potential living kidney donors. Kidney International 95, 896-904, doi:10.1016/j.kint.2018.11.029 (2019).

52           Galli, G. et al. HIV protease inhibitors and autoimmunity: An odd, but promising idea. Autoimmunity Reviews 18, doi:10.1016/j.autrev.2019.102370 (2019).

53           Gensous, N. et al. Age-related DNA methylation changes: Potential impact on skeletal muscle aging in humans. Frontiers in Physiology 10, doi:10.3389/fphys.2019.00996 (2019).

54           Gensous, N., Franceschi, C., Salvioli, S., Garagnani, P. & Bacalini, M. G. Down syndrome, ageing and epigenetics. Subcellular Biochemistry 91, 161-193, doi:10.1007/978-981-13-3681-2_7 (2019).

55           Gensous, N. et al. The impact of caloric restriction on the epigenetic signatures of aging. International Journal of Molecular Sciences 20, doi:10.3390/ijms20082022 (2019).

56           Glotz, D. et al. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. American Journal of Transplantation 19, 2865-2875, doi:10.1111/ajt.15397 (2019).

57           Goret, J. et al. Identification of Streptococcus sinensis from a patient with endocarditis using MALDI-TOF mass spectrometry, 16S rDNA- and sodA-based phylogeny. Journal of Microbiology, Immunology and Infection 52, 507-509, doi:10.1016/j.jmii.2018.04.004 (2019).

58           Gossec, L. et al. Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensus. Revue du Rhumatisme (Edition Francaise) 86, 555-562, doi:10.1016/j.rhum.2019.07.018 (2019).

59           Goutaudier, V. et al. C5B9 deposition in glomerular capillaries is associated with poor kidney allograft survival in antibody-mediated rejection. Frontiers in Immunology 10, doi:10.3389/fimmu.2019.00235 (2019).

60           Grillon, A. et al. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. Seminars in Arthritis and Rheumatism 48, 1105-1112, doi:10.1016/j.semarthrit.2018.09.007 (2019).

61           Guillaume, A. et al. Risk Factors of Early Kidney Graft Transplantectomy. Transplantation Proceedings 51, 3309-3314, doi:10.1016/j.transproceed.2019.07.027 (2019).

62           Guillotin, V. et al. Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysis. Revue du Rhumatisme (Edition Francaise) 86, 337-343, doi:10.1016/j.rhum.2019.03.005 (2019).

63           Henrot, P. et al. Assessment of subclinical atherosclerosis in systemic lupus erythematosus: A literature review and meta-analysis. Revue du Rhumatisme (Edition Francaise) 86, 232-240, doi:10.1016/j.rhum.2019.02.007 (2019).

64           Henrot, P., Truchetet, M. E., Fisher, G., Taïeb, A. & Cario, M. CCN proteins as potential actionable targets in scleroderma. Experimental Dermatology 28, 11-18, doi:10.1111/exd.13806 (2019).

65           Hyernard, C. et al. Atypical Presentation of Bacteremia in Older Patients Is a Risk Factor for Death. American Journal of Medicine 132, 1344-1352.e1341, doi:10.1016/j.amjmed.2019.04.049 (2019).

66           Kaminski, H., Couzi, L. & Merville, P. Late vs early-onset CMV infections in kidney transplantation, still a topical issue, reply to Ono et al. Transplant Infectious Disease 21, doi:10.1111/tid.13103 (2019).

67           Kaminski, H. et al. Different impact of ratg induction on cmv infection risk in d+r- and r+ ktrs. Journal of Infectious Diseases 220, 761-771, doi:10.1093/infdis/jiz194 (2019).

68           Kostine, M. et al. Addressing immune-related adverse events of cancer immunotherapy: How prepared are rheumatologists? Annals of the Rheumatic Diseases 78, 860-862, doi:10.1136/annrheumdis-2018-214748 (2019).

69           Kostine, M., Richez, C. & Schaeverbeke, T. Response to: ‘Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1’ by Michot et al and ‘Checkpoint inhibitor-associated immune arthritis’ by Arnaud et al. Annals of the Rheumatic Diseases 78, doi:10.1136/annrheumdis-2018-213691 (2019).

70           Kostine, M., Truchetet, M. E. & Schaeverbeke, T. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology (United Kingdom) 58, vii68-vii74, doi:10.1093/rheumatology/kez295 (2019).

71           Kröger, N. et al. Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. British Journal of Haematology 185, 725-732, doi:10.1111/bjh.15819 (2019).

72           La Combe, B. et al. Pneumonia-specific escherichia coli with distinct phylogenetic and virulence profiles, France, 2012–2014. Emerging Infectious Diseases 25, 710-718, doi:10.3201/eid2504.180944 (2019).

73           Lande, R. et al. CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis. Nature Communications 10, doi:10.1038/s41467-019-09683-z (2019).

74           Laplane, L., Duluc, D., Bikfalvi, A., Larmonier, N. & Pradeu, T. Beyond the tumour microenvironment. International Journal of Cancer, doi:10.1002/ijc.32343 (2019).

75           Laplane, L. et al. Why science needs philosophy. Proceedings of the National Academy of Sciences of the United States of America 116, 3948-3952, doi:10.1073/pnas.1900357116 (2019).

76           Larroquette, M. et al. Which place for avelumab in the management of urothelial carcinoma? Expert Opinion on Biological Therapy 19, 863-870, doi:10.1080/14712598.2019.1637412 (2019).

77           Lasserre, M., Domblides, C., Gross-goupil, M., Ravaud, A. & Daste, A. The interest of sequential treatment with immune check point inhibitors followed chemotherapy: A case report. Oral Oncology 94, 125-127, doi:10.1016/j.oraloncology.2019.05.001 (2019).

78           Lazaro, E., Houssin, C., Sentilhes, L., Blouin, L. & Fiore, M. Successful management of a pregnant woman with severe ANKRD26-related thrombocytopenia and anti-HPA-5b alloimmunization. Platelets, doi:10.1080/09537104.2019.1678116 (2019).

79           Lemoine, M. On the neurobiological redefinition of psychiatric symptoms: elimination, reduction, or what? Synthese 196, 2117-2133, doi:10.1007/s11229-016-1270-2 (2019).

80           Lemoine, M. R. PAUL THOMPSON & ROSS E.G. UPSHUR, Philosophy of Medicine: An Introduction, Oxon: Routledge, 2018, 194 pp. History and philosophy of the life sciences 41, 18, doi:10.1007/s40656-019-0257-y (2019).

81           Leroy, V. et al. Association of skin hyperpigmentation disorders with digital ulcers in systemic sclerosis: Analysis of a cohort of 239 patients. Journal of the American Academy of Dermatology 80, 478-484, doi:10.1016/j.jaad.2018.07.033 (2019).

82           Liu, H. et al. Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBD. BMC immunology 20, 42, doi:10.1186/s12865-019-0322-z (2019).

83           Loustau, C. et al. Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study. Revue du Rhumatisme (Edition Francaise) 86, 511-517, doi:10.1016/j.rhum.2019.07.016 (2019).

84           Machelart, I. et al. Visceral leishmaniasis with hemophagocytic lymphohistiocytosis in an immunocompetent adult. Medecine et Maladies Infectieuses 49, 548-550, doi:10.1016/j.medmal.2019.07.006 (2019).

85           Meunier, P. et al. Increased risk of mortality in systemic sclerosis-associated digital ulcers: a systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology 33, 405-409, doi:10.1111/jdv.15114 (2019).

86           Najm, A. et al. EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. RMD Open 5, doi:10.1136/rmdopen-2019-001014 (2019).

87           Pizzolato, G. et al. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 116, 11906-11915, doi:10.1073/pnas.1818488116 (2019).

88           Poiré, X. et al. Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission. American Journal of Hematology 94, 231-239, doi:10.1002/ajh.25355 (2019).

89           Pradeu, T. Immunology and individuality. eLife 8, doi:10.7554/eLife.47384 (2019).

90           Pradeu, T. Philosophy of CRISPR-Cas: Introduction to Eugene Koonin’s target paper and commentaries. Biology and Philosophy 34, doi:10.1007/s10539-018-9664-9 (2019).

91           Pradeu, T. & Moreau, J. F. CRISPR-Cas immunity: beyond nonself and defence. Biology and Philosophy 34, doi:10.1007/s10539-018-9665-8 (2019).

92           Prezelin-Reydit, M. et al. Prolonged dialysis duration is associated with graft failure and mortality after kidney transplantation: Results from the French transplant database. Nephrology Dialysis Transplantation 34, 538-545, doi:10.1093/ndt/gfy039 (2019).

93           Ralazamahaleo, M., Andreani, M., Di Luzio, A., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DQA1*01:27 allele by sequencing-based typing. HLA 94, 392-393, doi:10.1111/tan.13647 (2019).

94           Ralazamahaleo, M., Andreani, M., Galluccio, T., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DRB3*03:01:07 allele by sequencing-based typing. HLA 93, 240-241, doi:10.1111/tan.13481 (2019).

95           Ralazamahaleo, M., Andreani, M., Giustiniani, P., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DQA1*01:01:05 allele by sequencing-based typing. HLA 94, 172-173, doi:10.1111/tan.13569 (2019).

96           Ralazamahaleo, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DQB1*03:02:01:08 allele by sequencing-based typing. HLA 94, 335-336, doi:10.1111/tan.13579 (2019).

97           Ralazamahaleo, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DRB1*03:147 allele by sequencing-based typing. HLA 93, 53-54, doi:10.1111/tan.13419 (2019).

98           Richez, C. et al. Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR). Joint Bone Spine 86, eS2-eS103, doi:10.1016/S1297-319X(19)30154-X (2019).

99           Richez, C. et al. Practical management of patients on Janus kinase inhibitor (JAKi) therapy – the CRI fact sheets. Joint Bone Spine 86, eS1, doi:10.1016/S1297-319X(19)30153-8 (2019).

100         Rivière, E. et al. Neurosarcoidosis and infliximab therapy monitored by 18FDG PET/CT. QJM 112, 695-697, doi:10.1093/qjmed/hcz148 (2019).

101         Rondeau, E., Pradeu, T., Bikfalvi, A. & Larmonier, N. Characterizing causality in cancer. eLife 8, doi:10.7554/eLife.53755 (2019).

102         Ruiz-Irastorza, G. et al. Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. Autoimmunity Reviews 18, doi:10.1016/j.autrev.2019.102359 (2019).

103         Salliot, C. et al. Ultrasonography and detection of subclinical joints and tendons involvements in systemic lupus erythematosus (SLE) patients: A cross-sectional multicenter study. Revue du Rhumatisme (Edition Francaise) 86, 518-523, doi:10.1016/j.rhum.2019.07.005 (2019).

104         Scherlinger, M. et al. Rituximab in moderate to severe non-renal systemic lupus erythematosus: A reanalysis of the EXPLORER study. Annals of the Rheumatic Diseases 78, 1007-1010, doi:10.1136/annrheumdis-2018-214833 (2019).

105         Scherlinger, M. et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance. Revue du Rhumatisme (Edition Francaise) 86, 262-268, doi:10.1016/j.rhum.2019.03.015 (2019).

106         Scherlinger, M., Langlois, E., Germain, V. & Schaeverbeke, T. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Seminars in Arthritis and Rheumatism 48, 927-932, doi:10.1016/j.semarthrit.2018.07.005 (2019).

107         Scherlinger, M. et al. Biosimilars in France, to understand the stakes in order to use them well. Revue de Medecine Interne 40, 5-8, doi:10.1016/j.revmed.2018.10.383 (2019).

108         Scherlinger, M. & Schaeverbeke, T. Response to: ‘Switching from the bio-originators to biosimilar: Is it premature to recommend this procedure?’ by Cantini and Benucci. Annals of the Rheumatic Diseases 78, doi:10.1136/annrheumdis-2018-213021 (2019).

109         Scherlinger, M. & Schaeverbeke, T. Additional response to the correspondence: ‘Switching from the bio-originators to biosimilar: Is it premature to recommend this procedure?’ by Cantini and Bennuci. Annals of the Rheumatic Diseases 78, doi:10.1136/annrheumdis-2018-213342 (2019).

110         Schmidt-Hieber, M. et al. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. Annals of Hematology 98, 1755-1763, doi:10.1007/s00277-019-03669-z (2019).

111         Serpas, L. et al. Dnase1l3 deletion causes aberrations in length and end-motif frequencies in plasma DNA. Proceedings of the National Academy of Sciences of the United States of America 116, 641-649, doi:10.1073/pnas.1815031116 (2019).

112         Shouval, R. et al. Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia. Cancer 125, 3566-3573, doi:10.1002/cncr.32344 (2019).

113         Snanoudj, R. et al. Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression. Kidney International 95, 1471-1485, doi:10.1016/j.kint.2018.12.029 (2019).

114         Sommerer, C. et al. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney International 96, 231-244, doi:10.1016/j.kint.2019.01.041 (2019).

115         Stokes, J. et al. Bendamustine with Total Body Irradiation Limits Murine Graft-versus-Host Disease in Part Through Effects on Myeloid-Derived Suppressor Cells. Biology of Blood and Marrow Transplantation 25, 405-416, doi:10.1016/j.bbmt.2018.10.009 (2019).

116         Storci, G. et al. Genomic stability, anti-inflammatory phenotype, and up-regulation of the RNAseH2 in cells from centenarians. Cell Death and Differentiation 26, 1845-1858, doi:10.1038/s41418-018-0255-8 (2019).

117         Styczynski, J. et al. Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. Bone Marrow Transplantation 54, 2060-2071, doi:10.1038/s41409-019-0627-9 (2019).

118         Taton, B. et al. A prospective comparison of dynamic contrast-enhanced MRI and 51Cr-EDTA clearance for glomerular filtration rate measurement in 42 kidney transplant recipients. European Journal of Radiology 117, 209-215, doi:10.1016/j.ejrad.2019.02.002 (2019).

119         Tauzin, S. et al. Correction: The naturally processed CD95L elicits a c-Yes/Calcium/PI3K-driven cell migration pathway (PLoS Biol (2011) 9(6): e1001090. DOI: 10.1371/journal.pbio.1001090). PLoS Biology 17, doi:10.1371/journal.pbio.3000521 (2019).

120         Tome, M. et al. Inactivation of proprotein convertases in T cells inhibits PD-1 expression and creates a favorable immune microenvironment in colorectal cancer. Cancer Research 79, 5008-5021, doi:10.1158/0008-5472.CAN-19-0086 (2019).

121         Tumiotto, C. et al. Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles. PLoS ONE 14, doi:10.1371/journal.pone.0212347 (2019).

122         Venot, Q. et al. Author Correction: Targeted therapy in patients with PIK3CA-related overgrowth syndrome (Nature, (2018), 558, 7711, (540-546), 10.1038/s41586-018-0217-9). Nature 568, E6, doi:10.1038/s41586-019-1109-3 (2019).

123         Vercruysse, F. et al. Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Research and Therapy 21, doi:10.1186/s13075-019-1838-6 (2019).

124         Viallard, J. F., Vergier, B., Lazaro, E., Greib, C. & Pellegrin, J. L. Cutaneous necrotizing small-vessel vasculitis induced by acute hepatitis E. Clinical Case Reports 7, 1539-1541, doi:10.1002/ccr3.2167 (2019).

125         Victor, J. et al. Retrospective analysis of anti-TIF1gamma, anti-NXP2 and anti-SAE1/2 antibodies carriers at Bordeaux university hospital from November 2014 to February 2017. Revue de Medecine Interne 40, 70-81, doi:10.1016/j.revmed.2018.11.003 (2019).

126         Visentin, J. et al. Measuring anti-HLA antibody active concentration and affinity by surface plasmon resonance: Comparison with the luminex single antigen flow beads and T-cell flow cytometry crossmatch results. Molecular Immunology 108, 34-44, doi:10.1016/j.molimm.2019.02.006 (2019).

127         Zuber, J. et al. Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. Journal of the American Society of Nephrology 30, 2449-2463, doi:10.1681/ASN.2019040331 (2019).

1              Arbore, G. et al. Complement receptor CD46 co-stimulates optimal human CD8+ T cell effector function via fatty acid metabolism. Nature Communications 9, doi:10.1038/s41467-018-06706-z (2018).

2              Augusto, J. F., Truchetet, M. E., Charles, N., Blanco, P. & Richez, C. IgE in lupus pathogenesis: Friends or foes? Autoimmunity Reviews 17, 361-365, doi:10.1016/j.autrev.2017.11.027 (2018).

3              Baulier, G. et al. Guidelines for prophylaxis of Pneumocystis pneumonia cannot rely solely on CD4-cell count in autoimmune and inflammatory diseases. Clinical and Experimental Rheumatology 36, 0490-0493 (2018).

4              Bazin, T. et al. Microbiota Composition May Predict Anti-TNF Alpha Response in Spondyloarthritis Patients: An Exploratory Study. Scientific Reports 8, doi:10.1038/s41598-018-23571-4 (2018).

5              Belizna, C. et al. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews 17, 1153-1168, doi:10.1016/j.autrev.2018.05.012 (2018).

6              Billa, O. et al. Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort. PLoS ONE 13, doi:10.1371/journal.pone.0208657 (2018).

7              Bitoun, S. et al. Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications. Annals of the Rheumatic Diseases 77, 1835-1836, doi:10.1136/annrheumdis-2018-213183 (2018).

8              Bouthemy, C. et al. Improvement in HLA-typing by new sequence-specific oligonucleotides kits for HLA-A, -B, and -DRB1 loci. HLA 92, 279-287, doi:10.1111/tan.13382 (2018).

9              Calmettes, C. et al. Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis. Oncotarget 9, 26724-26736, doi:10.18632/oncotarget.25477 (2018).

10           Cargou, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-DPB1*763:01 allele by sequencing-based typing. HLA 92, 429-431, doi:10.1111/tan.13411 (2018).

11           Cargou, M., Ralazamahaleo, M., Blouin, L., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-C*07:639 allele by sequencing-based typing. HLA 92, 422-423, doi:10.1111/tan.13415 (2018).

12           Chasset, F. et al. Rare diseases that mimic systemic lupus erythematosus: Lupus mimickers. Revue du Rhumatisme Monographies 85, 245-252, doi:10.1016/j.monrhu.2018.07.001 (2018).

13           Christopeit, M. et al. Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. American Journal of Hematology 93, 1532-1542, doi:10.1002/ajh.25285 (2018).

14           Clément, J. et al. Two cases of tacrolimus-induced neutropenia: A probably under-diagnosed cause of neutropenia after solid-organ transplantation. Clinical Transplantation 32, doi:10.1111/ctr.13295 (2018).

15           Costedoat-Chalumeau, N. et al. A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clinical Pharmacology and Therapeutics 103, 1074-1082, doi:10.1002/cpt.885 (2018).

16           Courant, M. et al. The disappointing contribution of anti-human leukocyte antigen donor-specific antibodies characteristics for predicting allograft loss. Nephrology Dialysis Transplantation 33, 1853-1863, doi:10.1093/ndt/gfy088 (2018).

17           Courant, M. et al. Erratum: The disappointing contribution of anti-human leukocyte antigen donor-specific antibodies characteristics for predicting allograft loss (Nephrology Dialysis Transplantation (gfy088) DOI: 10.1093/NDT/gfy088). Nephrology Dialysis Transplantation 33, 1872, doi:10.1093/ndt/gfy182 (2018).

18           Dantal, J. et al. Sirolimus for secondary prevention of skin cancer in kidney transplant recipients: 5-year results. Journal of Clinical Oncology 36, 2612-2620, doi:10.1200/JCO.2017.76.6691 (2018).

19           Daste, A. et al. Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy. Oral Oncology 81, 116-118, doi:10.1016/j.oraloncology.2018.04.013 (2018).

20           De Latour, R. P. et al. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: A nationwide phase 2 study. Blood 132, 750-754, doi:10.1182/blood-2018-01-829630 (2018).

21           Di Primo, C., Taupin, J. L. & Visentin, J. Comments on “Direct quantitative measurement of the kinetics of HLA-specific antibody interactions with isolated HLA proteins”. Human Immunology 79, 129, doi:10.1016/j.humimm.2017.11.009 (2018).

22           Domblides, C. et al. Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates. AIDS 32, 461-468, doi:10.1097/QAD.0000000000001713 (2018).

23           Domblides, C. et al. Lung cancer in HIV-infected patients. Bulletin du Cancer 105, 111-119, doi:10.1016/j.bulcan.2017.11.002 (2018).

24           Dournes, G. et al. 3D ultrashort echo time MRI of the lung using stack-of-spirals and spherical k-Space coverages: Evaluation in healthy volunteers and parenchymal diseases. Journal of Magnetic Resonance Imaging 48, 1489-1497, doi:10.1002/jmri.26212 (2018).

25           Ducreux, S. et al. HLA-DRB3/4/5 mismatches are associated with increased risk of acute GVHD in 10/10 matched unrelated donor hematopoietic cell transplantation. American Journal of Hematology 93, 994-1001, doi:10.1002/ajh.25133 (2018).

26           Duffau, P. et al. Multimorbidity, age-related comorbidities and mortality: Association of activation, senescence and inflammation markers in HIV adults. AIDS 32, 1651-1660, doi:10.1097/QAD.0000000000001875 (2018).

27           Dupin, I., Contin-Bordes, C. & Berger, P. Fibrocytes in asthma and chronic obstructive pulmonary disease: Variations on the same theme. American Journal of Respiratory Cell and Molecular Biology 58, 288-298, doi:10.1165/rcmb.2017-0301PS (2018).

28           Eberl, G. & Pradeu, T. Towards a General Theory of Immunity? Trends in Immunology 39, 261-263, doi:10.1016/j.it.2017.11.004 (2018).

29           Eyraud, A. et al. Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature. British Journal of Dermatology 178, 650-658, doi:10.1111/bjd.15993 (2018).

30           Furudoï, A. et al. Adult Primary Immune Thrombocytopenia. American Journal of Surgical Pathology 42, 401-412, doi:10.1097/PAS.0000000000000994 (2018).

31           Gaillard, F. et al. The age-calibrated measured glomerular filtration rate improves living kidney donation selection process. Kidney International 94, 616-624, doi:10.1016/j.kint.2018.05.016 (2018).

32           Gallien, S. et al. Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis. HIV Medicine 19, 559-571, doi:10.1111/hiv.12643 (2018).

33           Gauthier, J. et al. Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin’s lymphoma undergoing allogeneic haematopoietic cell transplantation – A study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplantation 53, 400-409, doi:10.1038/s41409-017-0018-z (2018).

34           Gensous, N. et al. T follicular helper cells in autoimmune disorders. Frontiers in Immunology 9, doi:10.3389/fimmu.2018.01637 (2018).

35           Gensous, N. et al. Responders and non-responders to influenza vaccination: A DNA methylation approach on blood cells. Experimental Gerontology 105, 94-100, doi:10.1016/j.exger.2018.01.019 (2018).

36           Giroux, É. & Lemoine, M. Philosophy of medicine. The Philosophy of Science: A Companion, 464-509, doi:10.1093/oso/9780190690649.003.0013 (2018).

37           Glotz, D., Rostaing, L., Merville, P., Squifflet, J. P. & Lebranchu, Y. Intravenous Immunoglobulins in the Prevention of Rejection of a Second or Third Kidney Graft. Transplantation Proceedings 50, 70-71, doi:10.1016/j.transproceed.2017.11.010 (2018).

38           Goret, J. et al. Impact of the introduction of a nucleic acid amplification test for Clostridium difficile diagnosis on stool rejection policies. Gut Pathogens 10, doi:10.1186/s13099-018-0245-x (2018).

39           Greslehner, G. P. Conference report: The generalized theory of evolution, duesseldorf center for logic and philosophy of science, January 31 – February 3, 2018. Kriterion (Austria) 32, 93-97 (2018).

40           Guidicelli, G., Elsermans, V., Top, I., Ralazamahaleo, M. & Visentin, J. Characterization of the novel HLA-C*16:116 allele by sequencing-based typing. HLA 91, 309-311, doi:10.1111/tan.13228 (2018).

41           Guidicelli, G., Elsermans, V., Top, I., Ralazamahaleo, M. & Visentin, J. Characterization of the novel HLA-A*24:391 allele by sequencing-based typing. HLA 91, 292-293, doi:10.1111/tan.13229 (2018).

42           Guidicelli, G., Elsermans, V., Top, I., Ralazamahaleo, M. & Visentin, J. Characterization of the novel HLA-B*07:305 allele by sequencing-based typing. HLA 91, 296-297, doi:10.1111/tan.13224 (2018).

43           Guidicelli, G., Taupin, J. L. & Visentin, J. Predicted indirectly recognizable HLA epitopes (PIRCHE): Only the tip of the iceberg? American Journal of Transplantation 18, 521-522, doi:10.1111/ajt.14474 (2018).

44           Guidicelli, G. et al. Prevalence, distribution and amplitude of the complement interference phenomenon in single antigen flow beads assays. HLA 91, 507-513, doi:10.1111/tan.13263 (2018).

45           Guillotin, V. et al. Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysis. Joint Bone Spine 85, 663-668, doi:10.1016/j.jbspin.2018.03.006 (2018).

46           Henrot, P. et al. Assessment of subclinical atherosclerosis in systemic lupus erythematosus: A systematic review and meta-analysis. Joint Bone Spine 85, 155-163, doi:10.1016/j.jbspin.2017.12.009 (2018).

47           Howard, J. et al. Human Vγ9Vδ2 T lymphocytes in the immune response to P. Falciparum infection. Frontiers in Immunology 9, doi:10.3389/fimmu.2018.02760 (2018).

48           Jacquemin, C. et al. OX40L/OX40 axis impairs follicular and natural Treg function in human SLE. JCI insight 3, doi:10.1172/jci.insight.122167 (2018).

49           John, G. et al. Prevalence and Disease-Specific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study. Arthritis Care and Research 70, 1218-1227, doi:10.1002/acr.23454 (2018).

50           Juge, P. A. et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. New England Journal of Medicine 379, 2209-2219, doi:10.1056/NEJMoa1801562 (2018).

51           Juge, P. A. et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Revue du Rhumatisme (Edition Francaise) 85, 370-374, doi:10.1016/j.rhum.2017.09.003 (2018).

52           Kostine, M. et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Annals of the rheumatic diseases 77, 393-398, doi:10.1136/annrheumdis-2017-212257 (2018).

53           La Combe, B. et al. Decreased susceptibility to chlorhexidine affects a quarter of Escherichia coli isolates responsible for pneumonia in ICU patients. Intensive Care Medicine 44, 531-533, doi:10.1007/s00134-018-5061-8 (2018).

54           Labrousse, M. et al. Mosaicism in autoinflammatory diseases: Cryopyrin-associated periodic syndromes (CAPS) and beyond. A systematic review. Critical Reviews in Clinical Laboratory Sciences 55, 432-442, doi:10.1080/10408363.2018.1488805 (2018).

55           Laplane, L., Duluc, D., Larmonier, N., Pradeu, T. & Bikfalvi, A. The Multiple Layers of the Tumor Environment. Trends in Cancer 4, 802-809, doi:10.1016/j.trecan.2018.10.002 (2018).

56           Larroquette, M. et al. Dramatic response after anti PD1 treatment failure in a squamous cell carcinoma of the maxillary sinus. Oral Oncology 87, 207-209, doi:10.1016/j.oraloncology.2018.10.017 (2018).

57           Laurent, P. et al. Innate immunity in systemic sclerosis fibrosis: Recent advances. Frontiers in Immunology 9, doi:10.3389/fimmu.2018.01702 (2018).

58           Lemoine, M. & Pradeu, T. Dissecting the meanings of “physiology” to assess the vitality of the discipline. Physiology 33, 236-245, doi:10.1152/physiol.00015.2018 (2018).

59           Li, Z. et al. Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. American Journal of Hematology 93, 769-777, doi:10.1002/ajh.25087 (2018).

60           Loustau, C. et al. Effectiveness and safety of anakinra in gout patients with stage 4–5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study. Joint Bone Spine 85, 755-760, doi:10.1016/j.jbspin.2018.03.015 (2018).

61           Malard, F. et al. Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: On behalf of the ALWP of the EBMT and the MSKCC. Journal of Hematology and Oncology 11, doi:10.1186/s13045-018-0668-3 (2018).

62           Mekinian, A. et al. Chronic histiocytic intervillositis: Diagnosis and management. Revue de Medecine Interne 39, 117-121, doi:10.1016/j.revmed.2017.10.422 (2018).

63           Mercié, P. et al. Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial. The Lancet HIV 5, e126-e135, doi:10.1016/S2352-3018(18)30002-X (2018).

64           Nardini, C. et al. The epigenetics of inflammaging: The contribution of age-related heterochromatin loss and locus-specific remodelling and the modulation by environmental stimuli. Seminars in Immunology 40, 49-60, doi:10.1016/j.smim.2018.10.009 (2018).

65           Nguyen, Q. L., Merville, P. & Couzi, L. Impact of the individualized risks of end-stage renal disease on living kidney donor selection. Nephrology Dialysis Transplantation 33, 2245-2252, doi:10.1093/ndt/gfy145 (2018).

66           Pavlish, L. A. et al. Tracing the Distribution of Late 16th and Early 17th Century European Copper Artefacts in Southern Québec and Ontario, Canada. Archaeometry 60, 517-534, doi:10.1111/arcm.12323 (2018).

67           Poissonnier, A. et al. Disrupting the CD95–PLCγ1 interaction prevents Th17-driven inflammation. Nature Chemical Biology 14, 1079-1089, doi:10.1038/s41589-018-0162-9 (2018).

68           Pradeu, T. Philosophy of biology. The Philosophy of Science: A Companion, 430-463, doi:10.1093/oso/9780190690649.003.0012 (2018).

69           Pradeu, T. & Du Pasquier, L. Immunological memory: What’s in a name? Immunological Reviews 283, 7-20, doi:10.1111/imr.12652 (2018).

70           Ralazamahaleo, M., Elsermans, V., Top, I., Guidicelli, G. & Visentin, J. Characterization of the novel HLA-B*15:476 allele by sequencing-based typing. HLA 92, 412-413, doi:10.1111/tan.13416 (2018).

71           Rodrigue-Gervais, I. G. et al. The mitochondrial protease HtrA2 restricts the NLRP3 and AIM2 inflammasomes. Scientific Reports 8, doi:10.1038/s41598-018-26603-1 (2018).

72           Sacleux, S. C. et al. Post-operative complications in elderly onset inflammatory bowel disease: a population-based study. Alimentary Pharmacology and Therapeutics 47, 1652-1660, doi:10.1111/apt.14790 (2018).

73           Salliot, C. et al. Ultrasonography and detection of subclinical joints and tendons involvements in Systemic Lupus erythematosus (SLE) patients: A cross-sectional multicenter study. Joint Bone Spine 85, 741-745, doi:10.1016/j.jbspin.2018.01.013 (2018).

74           Salmon, D. et al. Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/ HCV coinfected patients. World Journal of Hepatology 10, 856-866, doi:10.4254/wjh.v10.i11.856 (2018).

75           Saraceni, F. et al. Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. Oncotarget 9, 3379-3393, doi:10.18632/oncotarget.23273 (2018).

76           Sawai, C. M. et al. Plasmacytoid dendritic cells are largely dispensable for the pathogenesis of experimental inflammatory bowel disease. Frontiers in Immunology 9, doi:10.3389/fimmu.2018.02475 (2018).

77           Schaeverbeke, T., Pham, T., Richez, C. & Wendling, D. Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI). Joint Bone Spine 85, 399-402, doi:10.1016/j.jbspin.2018.03.002 (2018).

78           Scherlinger, M., Alain, S. & Richez, C. Monitoring of Epstein–Barr virus (EBV)/cytomegalovirus (CMV)/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritis. Joint Bone Spine 85, 259-260, doi:10.1016/j.jbspin.2017.02.010 (2018).

79           Scherlinger, M., Bienvenu, T. C. M., Piffoux, M. & Séguin, P. MD-PhD trainings in France: Overview and future directions, from the French MD/PharmD-PhD students association AMPS. Medecine/Sciences 34, 464-472, doi:10.1051/medsci/20183405021 (2018).

80           Scherlinger, M. et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance. Joint Bone Spine 85, 561-567, doi:10.1016/j.jbspin.2017.10.003 (2018).

81           Scherlinger, M. et al. Systemic lupus erythematosus and systemic sclerosis: All roads lead to platelets. Autoimmunity Reviews 17, 625-635, doi:10.1016/j.autrev.2018.01.012 (2018).

82           Scherlinger, M., Schaeverbeke, T., Blanco, P. & Richez, C. Unilateral erosive arthritis in a patient with lupus. Revue du Rhumatisme (Edition Francaise) 85, 207-208, doi:10.1016/j.rhum.2017.07.017 (2018).

83           Shimoni, A. et al. Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation 24, 751-757, doi:10.1016/j.bbmt.2017.12.776 (2018).

84           Smirani, R. et al. Orofacial consequences of systemic sclerosis: A systematic review. Journal of Scleroderma and Related Disorders 3, 81-90, doi:10.1177/2397198317746966 (2018).

85           Smirani, R. et al. Impact of systemic sclerosis oral manifestations on patients’ health-related quality of life: A systematic review. Journal of Oral Pathology and Medicine 47, 808-815, doi:10.1111/jop.12739 (2018).

86           Songane, M., Khair, M. & Saleh, M. An updated view on the functions of caspases in inflammation and immunity. Seminars in Cell and Developmental Biology 82, 137-149, doi:10.1016/j.semcdb.2018.01.001 (2018).

87           Teyssonneau, D. et al. Treatment of spinal metastases in renal cell carcinoma: A critical review. Critical Reviews in Oncology/Hematology 125, 19-29, doi:10.1016/j.critrevonc.2018.02.017 (2018).

88           Tozatto-Maio, K. et al. Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation 24, 1657-1663, doi:10.1016/j.bbmt.2018.02.014 (2018).

89           Truchetet, M. E. & Pradeu, T. Re-thinking our understanding of immunity: Robustness in the tissue reconstruction system. Seminars in Immunology 36, 45-55, doi:10.1016/j.smim.2018.02.013 (2018).

90           Truchetet, M. E. & Schaeverbeke, T. Reply. Arthritis and Rheumatology 70, 2097-2098, doi:10.1002/art.40677 (2018).

91           Turpin, D. et al. Increase of follicular helper T cells skewed toward a Th1 profile in CVID patients with non-infectious clinical complications. Clinical Immunology 197, 130-138, doi:10.1016/j.clim.2018.09.006 (2018).

92           Venot, Q. et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature 558, 540-546, doi:10.1038/s41586-018-0217-9 (2018).

93           Vincenti, F. et al. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. American Journal of Transplantation 18, 2945-2954, doi:10.1111/ajt.14925 (2018).

94           Visentin, J. et al. Overcoming non-specific binding to measure the active concentration and kinetics of serum anti-HLA antibodies by surface plasmon resonance. Biosensors and Bioelectronics 117, 191-200, doi:10.1016/j.bios.2018.06.013 (2018).

1              Alunno, A. et al. Person-focused care for young people with rheumatic and musculoskeletal diseases: Young rheumatologists’ and EULAR Young PARE perspectives. RMD Open 3, doi:10.1136/rmdopen-2017-000514 (2017).

2              Assoumou, L. et al. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: A 2014 French nationwide study. Journal of Antimicrobial Chemotherapy 72, 1769-1773, doi:10.1093/jac/dkx042 (2017).

3              Bertrand, D. et al. Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study. Transplant International 30, 256-265, doi:10.1111/tri.12923 (2017).

4              Biscay, P. et al. Relevance assessment of requests for antineutrophil cytoplasmic antibodies detection: Retrospective study led in Bordeaux Hospital, France. Revue de Medecine Interne 38, 656-662, doi:10.1016/j.revmed.2017.06.003 (2017).

5              Blanchard, E., Truchetet, M. E., Machelart, I., Séneschal, J. & Raherison-Semjen, C. Respiratory infections associated with anti-TNFα agents. Medecine et Maladies Infectieuses 47, 375-381, doi:10.1016/j.medmal.2017.05.002 (2017).

6              Bommart, S. et al. Smoking-associated morbidities on computed tomography lung cancer screens in HIV-infected smokers. HIV Medicine 18, 787-789, doi:10.1111/hiv.12517 (2017).

7              Boulon, C. et al. Reproducibility of capillaroscopic classifications of systemic sclerosis: Results from the SCLEROCAP study. Rheumatology (United Kingdom) 56, 1713-1720, doi:10.1093/rheumatology/kex246 (2017).

8              Caillard, S. et al. A French cohort study of kidney retransplantation after post-transplant lymphoproliferative disorders. Clinical Journal of the American Society of Nephrology 12, 1663-1670, doi:10.2215/CJN.03790417 (2017).

9              Canaani, J. et al. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. American Journal of Hematology 92, 653-659, doi:10.1002/ajh.24737 (2017).

10           Carrieri, M. P. et al. Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey). PLoS ONE 12, doi:10.1371/journal.pone.0171645 (2017).

11           Chiu, L. et al. Protective microbiota: From localized to long-reaching co-immunity. Frontiers in Immunology 8, doi:10.3389/fimmu.2017.01678 (2017).

12           Contis, A. et al. Efficacy and safety of propranolol for epistaxis in hereditary haemorrhagic telangiectasia: retrospective, then prospective study, in a total of 21 patients. Clinical Otolaryngology 42, 911-917, doi:10.1111/coa.12821 (2017).

13           Contis, A. et al. Neutrophil-derived mitochondrial DNA promotes receptor activator of nuclear factor κB and its ligand signalling in rheumatoid arthritis. Rheumatology (United Kingdom) 56, 1200-1205, doi:10.1093/rheumatology/kex041 (2017).

14           Dagenais, M. et al. The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis. OncoImmunology 6, doi:10.1080/2162402X.2017.1287247 (2017).

15           Darrigade, A. S. et al. Pattern and severity of psoriasiform eruptions in patients with inflammatory bowel diseases, arthritis or skin inflammatory disorders treated with TNF-alpha inhibitors. Acta Dermato-Venereologica 97, 731-734, doi:10.2340/00015555-2636 (2017).

16           Daste, A. et al. Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment. Oral Oncology 64, e1-e3, doi:10.1016/j.oraloncology.2016.10.020 (2017).

17           Daste, A. et al. Immune checkpoint inhibitors and elderly people: A review. European Journal of Cancer 82, 155-166, doi:10.1016/j.ejca.2017.05.044 (2017).

18           Desclaux, A., Lazaro, E., Pinaquy, J. B., Yacoub, M. & Viallard, J. F. Renal intravascular large B-cell lymphoma: A case report and review of the literature. Internal Medicine 56, 827-833, doi:10.2169/internalmedicine.56.6406 (2017).

19           Di Lorenzo, B., Déchanet-Merville, J. & Silva-Santos, B. Peripheral clonal selection shapes the human γδ T-cell repertoire. Cellular and Molecular Immunology 14, 733-735, doi:10.1038/cmi.2017.51 (2017).

20           Diamanti, M. A. et al. IKKα controls ATG16L1 degradation to prevent ER stress during inflammation. Journal of Experimental Medicine 214, 423-437, doi:10.1084/jem.20161867 (2017).

21           Domblides, C., Antoine, M., Lavole, A., Cadranel, J. & Wislez, M. Crizotinib for ROS1-rearranged non-small cell lung cancer patients. Bulletin du Cancer 104, 303-310, doi:10.1016/j.bulcan.2017.01.008 (2017).

22           Domblides, C., Chaabane, N. & Wislez, M. Toward new modalities of surveillance in lung cancer patients? Bulletin du Cancer 104, 703-704, doi:10.1016/j.bulcan.2017.07.004 (2017).

23           Domblides, C., Masse, L. & Veillon, R. Meningeal carcinomatosis in lung cancer. Revue des Maladies Respiratoires Actualites 9, 288-298, doi:10.1016/S1877-1203(17)30060-5 (2017).

24           Domblides, C., Ruppert, A. M., Antoine, M. & Wislez, M. Immunotherapy’s new challenge: Identification of predictive biomarkers for tumor response. Translational Cancer Research 6, S306-S308, doi:10.21037/tcr.2017.03.04 (2017).

25           Dubois-Laforgue, D. et al. Intellectual disability in patients with MODY due to hepatocyte nuclear factor 1B (HNF1B) molecular defects. Diabetes and Metabolism 43, 89-92, doi:10.1016/j.diabet.2016.10.003 (2017).

26           Dumas, P. Y. et al. Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia. Oncotarget 8, 79126-79136, doi:10.18632/oncotarget.15988 (2017).

27           Duricova, D. et al. Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study. Journal of Crohn’s and Colitis 11, 1326-1334, doi:10.1093/ecco-jcc/jjx092 (2017).

28           Feuillet, P. et al. Prevalence of and factors associated with depression among people living with HIV in France. HIV Medicine 18, 383-394, doi:10.1111/hiv.12438 (2017).

29           Forcade, E. et al. An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI insight 2, doi:10.1172/jci.insight.92111 (2017).

30           Furman, D. et al. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nature Medicine 23, 174-184, doi:10.1038/nm.4267 (2017).

31           Gensous, N. et al. The epigenetic landscape of age-related diseases: the geroscience perspective. Biogerontology 18, 549-559, doi:10.1007/s10522-017-9695-7 (2017).

32           Gensous, N., Doassans-Comby, L., Lazaro, E. & Duffau, P. Systemic lupus erythematosus and contraception: A systematic literature review. Revue de Medecine Interne 38, 358-367, doi:10.1016/j.revmed.2016.12.009 (2017).

33           Gensous, N. et al. Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review. Arthritis research & therapy 19, 238, doi:10.1186/s13075-017-1442-6 (2017).

34           Gensous, N., Schmitt, N., Richez, C., Ueno, H. & Blanco, P. T follicular helper cells, interleukin-21 and systemic lupus erythematosus. Rheumatology (United Kingdom) 56, 516-523, doi:10.1093/rheumatology/kew297 (2017).

35           Ghisdal, L. et al. Genome-Wide Association Study of Acute Renal Graft Rejection. American Journal of Transplantation 17, 201-209, doi:10.1111/ajt.13912 (2017).

36           Goret, J. et al. Interaction of Mycoplasma hominis PG21 with human dendritic cells: Interleukin-23-inducing mycoplasmal lipoproteins and inflammasome activation of the cell. Journal of Bacteriology 199, doi:10.1128/JB.00213-17 (2017).

37           Gossec, L. et al. Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France. Revue du Rhumatisme (Edition Francaise) 84, 123-131, doi:10.1016/j.rhum.2016.12.021 (2017).

38           Gros, F. X. et al. Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation. Bone Marrow Transplantation 52, 1047-1048, doi:10.1038/bmt.2017.78 (2017).

39           Guilhem, A. et al. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients. PLoS ONE 12, doi:10.1371/journal.pone.0188943 (2017).

40           Henrot, P., Truchetet, M. E. & Cario-Andre, M. Are Murine Fibroblasts Responsible for Fibrosis Reversion? Comment on the Article by Luchetti et al. Arthritis and Rheumatology 69, 1703, doi:10.1002/art.40139 (2017).

41           Howard, J. et al. The Antigen-Presenting Potential of Vγ39Vδ 2 T Cells during Plasmodium falciparum Blood-Stage Infection. Journal of Infectious Diseases 215, 1569-1579, doi:10.1093/infdis/jix149 (2017).

42           Jacquemin, C. et al. Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis. British Journal of Dermatology 177, 1367-1375, doi:10.1111/bjd.15550 (2017).

43           Jasiek, M. et al. A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren’s syndrome. Rheumatology (United Kingdom) 56, 362-370, doi:10.1093/rheumatology/kew376 (2017).

44           John, G. et al. The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: An international multicentre study. Rheumatology (United Kingdom) 56, 1874-1883, doi:10.1093/rheumatology/kex230 (2017).

45           Juge, P. A. et al. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. European Respiratory Journal 49, doi:10.1183/13993003.02314-2016 (2017).

46           Juge, P. A. et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine 84, 595-598, doi:10.1016/j.jbspin.2016.09.020 (2017).

47           Khairallah, C., Déchanet-Merville, J. & Capone, M. γδ T cell-mediated immunity to cytomegalovirus infection. Frontiers in Immunology 8, doi:10.3389/fimmu.2017.00105 (2017).

48           Kleinmann, J. F. et al. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews 16, 650-657, doi:10.1016/j.autrev.2017.04.011 (2017).

49           Kostine, M. et al. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. Revue de Medecine Interne 38, 513-525, doi:10.1016/j.revmed.2017.01.004 (2017).

50           Laurent, P. et al. Immune-mediated repair: A matter of plasticity. Frontiers in Immunology 8, doi:10.3389/fimmu.2017.00454 (2017).

51           Lawand, M., Déchanet-Merville, J. & Dieu-Nosjean, M. C. Key features of gamma-delta T-cell subsets in human diseases and their immunotherapeutic implications. Frontiers in Immunology 8, doi:10.3389/fimmu.2017.00761 (2017).

52           Lazaro, E. et al. Biotherapies in systemic lupus erythematosus: New targets. Joint Bone Spine 84, 267-274, doi:10.1016/j.jbspin.2016.07.004 (2017).

53           Le Gallo, M., Poissonnier, A., Blanco, P. & Legembre, P. CD95/Fas, non-apoptotic signaling pathways, and kinases. Frontiers in Immunology 8, doi:10.3389/fimmu.2017.01216 (2017).

54           Lemoine, M. Animal extrapolation in preclinical studies: An analysis of the tragic case of TGN1412. Studies in History and Philosophy of Science Part C :Studies in History and Philosophy of Biological and Biomedical Sciences 61, 35-45, doi:10.1016/j.shpsc.2016.12.004 (2017).

55           Lemoine, M. The promises of precision psychiatry. Journal de Medecine Legale Droit Medical 60, 31-34 (2017).

56           Machelart, I. et al. Graft infection after a Bentall procedure: A case series and systematic review of the literature. Diagnostic Microbiology and Infectious Disease 88, 158-162, doi:10.1016/j.diagmicrobio.2017.03.002 (2017).

57           Magro, L. et al. Management of the chronic graft versus host disease: Guidelines from the Francophone society of bone marrow transplantation and cellular therapies (SFGM-TC). Bulletin du Cancer 104, S145-S168, doi:10.1016/j.bulcan.2017.10.023 (2017).

58           Marlin, R. et al. Sensing of cell stress by human γδ TCR-dependent recognition of annexin A2. Proceedings of the National Academy of Sciences of the United States of America 114, 3163-3168, doi:10.1073/pnas.1621052114 (2017).

59           Martínez, C. et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for hodgkin lymphoma: A registry study of the lymphoma working party of the european society for blood and marrow transplantation. Journal of Clinical Oncology 35, 3425-3432, doi:10.1200/JCO.2017.72.6869 (2017).

60           Monlun, M., Hyernard, C., Blanco, P., Lartigue, L. & Faustin, B. Mitochondria as Molecular Platforms Integrating Multiple Innate Immune Signalings. Journal of Molecular Biology 429, 1-13, doi:10.1016/j.jmb.2016.10.028 (2017).

61           Moreau, J. F. et al. The emerging role of ECM crosslinking in T cell mobility as a hallmark of immunosenescence in humans. Ageing Research Reviews 35, 322-335, doi:10.1016/j.arr.2016.11.005 (2017).

62           Mourad, G. et al. Incidence of Posttransplantation Diabetes Mellitus in de Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression with 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial. Transplantation 101, 1924-1934, doi:10.1097/TP.0000000000001453 (2017).

63           Ouisse, L. H. et al. Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: A rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies. BMC Biotechnology 17, doi:10.1186/s12896-016-0322-5 (2017).

64           Ozanne, A. et al. Activation, senescence and inflammation markers in HIV patients: Association with renal function. AIDS 31, 1119-1128, doi:10.1097/QAD.0000000000001461 (2017).

65           Picat, M. Q. et al. Integrative analysis of immunological data to explore chronic immune T-cell activation in successfully treated HIV patients. PLoS ONE 12, doi:10.1371/journal.pone.0169164 (2017).

66           Pradeu, T. Thirty years of Biology & Philosophy: philosophy of which biology? Biology and Philosophy 32, 149-167, doi:10.1007/s10539-016-9558-7 (2017).

67           Qu, K. et al. Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors. Cancer Cell 32, 27-41.e24, doi:10.1016/j.ccell.2017.05.008 (2017).

68           Richez, C., Barnetche, T., Schaeverbeke, T. & Truchetet, M. E. Rheumatoid arthritis: An understanding of the etiopathogenesis still in progress. Revue du Rhumatisme Monographies 84, 311-317, doi:10.1016/j.monrhu.2017.07.006 (2017).

69           Richez, C., Truchetet, M. E., Kostine, M., Schaeverbeke, T. & Bannwarth, B. Efficacy of baricitinib in the treatment of rheumatoid arthritis. Expert Opinion on Pharmacotherapy 18, 1399-1407, doi:10.1080/14656566.2017.1359256 (2017).

70           Rivière, E. et al. Takayasu arteritis and spondyloarthritis: Coincidence or association? A study of 14 cases. Journal of Rheumatology 44, 1011-1017, doi:10.3899/jrheum.160762 (2017).

71           Rivière, E. et al. Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study. Journal of Neurology 264, 1218-1226, doi:10.1007/s00415-017-8519-7 (2017).

72           Ruiz-Irastorza, G. et al. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmunity Reviews 16, 826-832, doi:10.1016/j.autrev.2017.05.017 (2017).

73           Scherlinger, M., Guillet, S., Doutre, M. S., Beylot-Barry, M. & Pham-Ledard, A. Pyoderma gangrenosum with extensive pulmonary involvement. Journal of the European Academy of Dermatology and Venereology 31, e214-e216, doi:10.1111/jdv.13976 (2017).

74           Scherlinger, M., Schaeverbeke, T., Blanco, P. & Richez, C. A unilateral erosive arthritis in a patient with systemic lupus erythematosus. Joint Bone Spine 84, 245-246, doi:10.1016/j.jbspin.2016.03.009 (2017).

75           Scherlinger, M., Schaeverbeke, T., Truchetet, M. E. & Federation Hospitalo Universitaire, A. Serum sickness-like disease after switching to biosimilar infliximab. Rheumatology (Oxford, England) 56, 2032-2034, doi:10.1093/rheumatology/kex268 (2017).

76           Scherlinger, M. et al. New Insights on Platelets and Platelet-Derived Microparticles in Systemic Lupus Erythematosus. Current Rheumatology Reports 19, doi:10.1007/s11926-017-0678-0 (2017).

77           Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases 76, 960-977, doi:10.1136/annrheumdis-2016-210715 (2017).

78           Thiébaut, R. et al. Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients. AIDS 31, 2355-2365, doi:10.1097/QAD.0000000000001628 (2017).

79           Thilly, N. et al. Cost-effectiveness of home telemonitoring in chronic kidney disease patients at different stages by a pragmatic randomized controlled trial (eNephro): Rationale and study design. BMC Nephrology 18, doi:10.1186/s12882-017-0529-2 (2017).

80           Touzot, M. et al. Proliferative lupus nephritis in the absence of overt systemic lupus erythematosus. Medicine (United States) 96, doi:10.1097/MD.0000000000009017 (2017).

81           Tron, L. et al. Levels and determinants of breast and cervical cancer screening uptake in HIV-infected women compared with the general population in France. HIV Medicine 18, 181-195, doi:10.1111/hiv.12412 (2017).

82           Truchetet, M. E. et al. Association of the Presence of Anti–Carbamylated Protein Antibodies in Early Arthritis With a Poorer Clinical and Radiologic Outcome: Data From the French ESPOIR Cohort. Arthritis and Rheumatology 69, 2292-2302, doi:10.1002/art.40237 (2017).

83           Viallard, J. F. et al. A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID). Revue de Medecine Interne 38, 578-584, doi:10.1016/j.revmed.2017.05.009 (2017).

84           Visentin, J. et al. Reassessment of t lymphocytes crossmatches results prediction with luminex class i single antigen flow beads assay. Transplantation 101, 624-630, doi:10.1097/TP.0000000000001239 (2017).

85           Visentin, J., Guidicelli, G. & Taupin, J. L. Conformational Variants of HLA-I Antigens on Luminex Single Antigen Beads. Transplantation 101, e152-e153, doi:10.1097/TP.0000000000001607 (2017).

1              Bachelet, T. et al. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: A pilot study. Clinical Transplantation 29, 439-446, doi:10.1111/ctr.12535 (2015).

2              Bentebibel, S. E., Jacquemin, C., Schmitt, N. & Ueno, H. Analysis of human blood memory T follicular helper subsets. T Follicular Helper Cells: Methods and Protocols, 187-197, doi:10.1007/978-1-4939-2498-1_16 (2015).

3              Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M. E. & Schaeverbeke, T. Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis. BMC Medicine 13, doi:10.1186/s12916-015-0455-8 (2015).

4              Bonneville, M. et al. Chicago 2014 – 30 years of γδ T cells. Cellular Immunology 296, 3-9, doi:10.1016/j.cellimm.2014.11.001 (2015).

5              Bunin, A. et al. Protein Tyrosine Phosphatase PTPRS Is an Inhibitory Receptor on Human and Murine Plasmacytoid Dendritic Cells. Immunity 43, 277-288, doi:10.1016/j.immuni.2015.07.009 (2015).

6              Cazanave, C. et al. Switch to rilpivirine/emtricitabine/tenofovir single-tablet regimen of human immunodeficiency virus-1 RNA-suppressed patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014. Open Forum Infectious Diseases 2, doi:10.1093/ofid/ofv018 (2015).

7              Courties, A. et al. AA amyloidosis treated with tocilizumab: Case series and updated literature review. Amyloid 22, 84-92, doi:10.3109/13506129.2014.1002031 (2015).

8              Coutzac, C. et al. Association between infliximab trough levels and the occurrence of paradoxical manifestations in patients with inflammatory bowel disease: A case-control study. Journal of Crohn’s and Colitis 9, 982-987, doi:10.1093/ecco-jcc/jjv159 (2015).

9              Couzi, L. et al. Difference in outcomes after antibody-mediated rejection between abo-incompatible and positive cross-match transplantations. Transplant International 28, 1205-1215, doi:10.1111/tri.12621 (2015).

10           Couzi, L. et al. Incidence and Outcome of C4d Staining with Tubulointerstitial Inflammation in Blood Group-incompatible Kidney Transplantation. Transplantation 99, 1487-1494, doi:10.1097/TP.0000000000000556 (2015).

11           Couzi, L., Pitard, V., Moreau, J. F., Merville, P. & Déchanet-Merville, J. Direct and indirect effects of cytomegalovirus-induced γδ T cells after kidney transplantation. Frontiers in Immunology 6, doi:10.3389/fimmu.2015.00003 (2015).

12           Debiais, S. et al. Ethical considerations for craniectomy in malignant middle cerebral artery infarction: Should we still deny our patient a life-saving procedure? International Journal of Stroke 10, E71, doi:10.1111/ijs.12562 (2015).

13           Domblides, C., Cortot, A. & Wislez, M. MET exon 14 mutation, new target in lung sarcomatoid carcinoma. Bulletin du cancer 102, 966 (2015).

14           Domblides, C. et al. Lung cancer in the HIV population. Revue des Maladies Respiratoires Actualites 7, 531-538, doi:10.1016/S1877-1203(16)30037-4 (2015).

15           Douglas, T., Champagne, C., Morizot, A., Lapointe, J. M. & Saleh, M. The inflammatory caspases-1 and-11 mediate the pathogenesis of dermatitis in sharpin-deficient mice. Journal of Immunology 195, 2365-2373, doi:10.4049/jimmunol.1500542 (2015).

16           Doutrelon, C. et al. Hydrocycarbamide induced fever: Four cases and literature review. Revue de Medecine Interne 36, 73-77, doi:10.1016/j.revmed.2013.12.008 (2015).

17           Duffau, P. et al. Promotion of inflammatory arthritis by interferon regulatory factor 5 in a mouse model. Arthritis and Rheumatology 67, 3146-3157, doi:10.1002/art.39321 (2015).

18           Duffau, P. et al. Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients. AIDS 29, 2099-2108, doi:10.1097/QAD.0000000000000807 (2015).

19           Dupaul-Chicoine, J. et al. The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity. Immunity 43, 751-763, doi:10.1016/j.immuni.2015.08.013 (2015).

20           Eckert, C. et al. Prevalence and pathogenicity of binary toxin-positive Clostridium difficile strains that do not produce toxins A and B. New Microbes and New Infections 3, 12-17, doi:10.1016/j.nmni.2014.10.003 (2015).

21           Fabre, A. et al. Opportunistic pulmonary Bordetella hinzii infection after avian exposure. Emerging Infectious Diseases 21, 2122-2126, doi:10.3201/eid2112.150400 (2015).

22           Gazal, S. et al. Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. Annals of the Rheumatic Diseases 74, doi:10.1136/annrheumdis-2013-204581 (2015).

23           Goret, J. et al. Comparison of a novel chemiluminescent based algorithm to three algorithmic approaches for the laboratory diagnosis of Clostridium difficile infection. Gut Pathogens 7, doi:10.1186/s13099-015-0079-8 (2015).

24           Guenot, M. et al. Phosphoantigen burst upon plasmodium falciparum schizont rupture can distantly activate Vγ9Vδ2 T Cells. Infection and Immunity 83, 3816-3824, doi:10.1128/IAI.00446-15 (2015).

25           Guerville, F. et al. TCR-dependent sensitization of human γδ T cells to non-myeloid IL-18 in cytomegalovirus and tumor stress surveillance. OncoImmunology 4, doi:10.1080/2162402X.2014.1003011 (2015).

26           Hellemans, R. et al. Daclizumab versus rabbit antithymocyte globulin in high-risk renal transplants: Five-year follow-up of a randomized study. American Journal of Transplantation 15, 1923-1932, doi:10.1111/ajt.13191 (2015).

27           Houx, L. et al. Musculoskeletal symptoms in patients with cryopyrin-associated periodic syndromes: A large database study. Arthritis and Rheumatology 67, 3027-3036, doi:10.1002/art.39292 (2015).

28           Jacquemin, C. et al. OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response. Immunity 42, 1159-1170, doi:10.1016/j.immuni.2015.05.012 (2015).

29           Janikashvili, N., Chikovani, T., Audia, S., Bonnotte, B. & Larmonier, N. T Lymphocyte Plasticity in Autoimmunity and Cancer. BioMed Research International 2015, doi:10.1155/2015/540750 (2015).

30           Janikashvili, N. et al. Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory forkhead box protein 3-positive CD8+ T lymphocytes. Journal of Allergy and Clinical Immunology 135, 1614-1624.e1614, doi:10.1016/j.jaci.2014.12.1868 (2015).

31           Kabelitz, D. & Déchanet-Merville, J. Editorial: “Recent advances in gamma/delta T cell biology: New ligands, new functions, and new translational perspectives”. Frontiers in Immunology 6, doi:10.3389/fimmu.2015.00371 (2015).

32           Kaminski, H., Couzi, L., Déchanet-Merville, J. & Merville, P. Immunomonitoring for cytomegalovirus infection in kidney transplantation: Development and prospects. Nephrologie et Therapeutique 11, 465-473, doi:10.1016/j.nephro.2015.03.005 (2015).

33           Khairallah, C. et al. γδ T Cells Confer Protection against Murine Cytomegalovirus (MCMV). PLoS Pathogens 11, 1-22, doi:10.1371/journal.ppat.1004702 (2015).

34           Kolev, M. et al. Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses. Immunity 42, 1033-1047, doi:10.1016/j.immuni.2015.05.024 (2015).

35           Krzywinska, E. et al. Identification of Anti-tumor Cells Carrying Natural Killer (NK) Cell Antigens in Patients With Hematological Cancers. EBioMedicine 2, 1364-1376, doi:10.1016/j.ebiom.2015.08.021 (2015).

36           Lazaro, E. & Morel, J. Management of neutropenia in patients with rheumatoid arthritis. Joint Bone Spine 82, 235-239, doi:10.1016/j.jbspin.2015.01.005 (2015).

37           Lazaro, E. & Morel, J. The occurrence of neutropenia in a patient with rheumatoid arthritis. Revue du Rhumatisme (Edition Francaise) 82, 75-79, doi:10.1016/j.rhum.2014.12.007 (2015).

38           Leroux, M. et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: A descriptive cohort study. Lupus 24, 1384-1391, doi:10.1177/0961203315591027 (2015).

39           Majeed, B. A. et al. Functional aortic stiffness: Role of CD4+ T lymphocytes. Frontiers in Physiology 6, doi:10.3389/fphys.2015.00235 (2015).

40           Miot, C. et al. IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells. Gut 64, 1466-1475, doi:10.1136/gutjnl-2013-306604 (2015).

41           Mocroft, A. et al. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. PLoS Medicine 12, doi:10.1371/journal.pmed.1001809 (2015).

42           Neau-Cransac, M. et al. Evolution of serum and intra-graft donor-specific anti-HLA antibodies in a patient with two consecutive liver transplantations. Transplant Immunology 33, 58-62, doi:10.1016/j.trim.2015.08.002 (2015).

43           Petitpierre, F. et al. Embolization of renal arteries before transplantation in patients with polycystic kidney disease: a single institution long-term experience. European Radiology 25, 3263-3271, doi:10.1007/s00330-015-3730-3 (2015).

44           Raffray, L. et al. Septic shock sera containing circulating histones induce dendritic cell-regulated necrosis in fatal septic shock patients. Critical Care Medicine 43, e107-e116, doi:10.1097/CCM.0000000000000879 (2015).

45           Raffray, L., Rivière, P., Bonnet, H., Duffau, P. & Longy-Boursier, M. Granulomatous hepatitis revealing a Mycobacterium bovis widespread infection following intravesical BCG therapy. Revue de Medecine Interne 36, 626-630, doi:10.1016/j.revmed.2014.10.361 (2015).

46           Rigothier, C. et al. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody. American Journal of Kidney Diseases 66, 331-336, doi:10.1053/j.ajkd.2015.03.039 (2015).

47           Rosenthal, E. et al. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: The Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey. HIV Medicine 16, 230-239, doi:10.1111/hiv.12204 (2015).

48           Rostaing, L. et al. Fibrosis progression according to epithelial-mesenchymal transition profile: A randomized trial of everolimus versus CsA. American Journal of Transplantation 15, 1303-1312, doi:10.1111/ajt.13132 (2015).

49           Schaeverbeke, T. et al. Immunogenicity of biologic agents in rheumatoid arthritis patients: Lessons for clinical practice. Rheumatology (United Kingdom) 55, 210-220, doi:10.1093/rheumatology/kev277 (2015).

50           Schaeverbeke, T., Truchetet, M. E. & Richez, C. Role of environmental factors in spondyloarthritis. Revue du Rhumatisme Monographies 82, 3-6, doi:10.1016/j.monrhu.2014.11.001 (2015).

51           Schmitt, N. & Ueno, H. Regulation of human helper T cell subset differentiation by cytokines. Current Opinion in Immunology 34, 130-136, doi:10.1016/j.coi.2015.03.007 (2015).

52           Seng, R. et al. Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretroviral therapy. AIDS 29, 595-607, doi:10.1097/QAD.0000000000000571 (2015).

53           Sicard, A. et al. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. Journal of the American Society of Nephrology 26, 457-467, doi:10.1681/ASN.2013101144 (2015).

54           Terrier, B. et al. Granulomatosis with polyangiitis: Endoscopic management of tracheobronchial stenosis: Results from a multicentre experience. Rheumatology (United Kingdom) 54, 1852-1857, doi:10.1093/rheumatology/kev129 (2015).

55           Tuffigo, M. et al. Successful use of recombinant factor VIIa in a patient with acquired Glanzmann thrombasthenia. Haemophilia 21, e116-e118, doi:10.1111/hae.12589 (2015).

56           Ueno, H. & Blanco, P. OX40/OX40L axis: Not a friend in autoimmunity. Oncotarget 6, 21779-21780, doi:10.18632/oncotarget.4973 (2015).

57           Vandenhende, M. A. et al. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study). Antiviral Therapy 20, 655-660, doi:10.3851/IMP2949 (2015).

58           Vandenhende, M. A. et al. Cancer-related causes of death among HIV-infected patients in France in 2010: Evolution since 2000. PLoS ONE 10, doi:10.1371/journal.pone.0129550 (2015).

59           Viot, B. et al. Two-year post-transplantation cytomegalovirus DNAemia in asymptomatic kidney transplant recipients: Incidence, risk factors, and outcome. Transplant Infectious Disease 17, 497-509, doi:10.1111/tid.12408 (2015).

60           Visentin, J., Guidicelli, G., Moreau, J. F., Lee, J. H. & Taupin, J. L. Deciphering allogeneic antibody response against native and denatured HLA epitopes in organ transplantation. European Journal of Immunology 45, 2111-2121, doi:10.1002/eji.201445340 (2015).

61           Visentin, J. et al. Evaluation of the iBeads assay as a tool for identifying class I HLA antibodies. Human Immunology 76, 651-656, doi:10.1016/j.humimm.2015.09.012 (2015).

62           Visentin, J., Guidicelli, G. & Taupin, J. L. Assessing HLA antibody strength: Have we thought about everything? American Journal of Transplantation 15, 3271, doi:10.1111/ajt.13452 (2015).

63           Visentin, J. et al. Clinical impact of preformed donor-specific denatured class I HLA antibodies after kidney transplantation. Clinical Transplantation 29, 393-402, doi:10.1111/ctr.12529 (2015).

64           Watkins, A. A. et al. IRF5 deficiency ameliorates lupus but promotes atherosclerosis and metabolic dysfunction in a mouse model of lupus-associated atherosclerosis. Journal of Immunology 194, 1467-1479, doi:10.4049/jimmunol.1402807 (2015).

65           Yassine, H. et al. Experimental evidence for IS1294b-mediated transposition of the blaCMY-2 cephalosporinase gene in Enterobacteriaceae. Journal of Antimicrobial Chemotherapy 70, 697-700, doi:10.1093/jac/dku472 (2015).

66           Alho, A. C. et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood 127, 646-657, doi:10.1182/blood-2015-10-672345 (2016).

67           Alizadeh, D. & Larmonier, N. Generation and expansion of T helper 17 lymphocytes ex vivo. Methods in Molecular Biology 1371, 101-113, doi:10.1007/978-1-4939-3139-2_7 (2016).

68           Arabzadeh, A. et al. Carcinoembryonic antigen cell adhesion molecule 1 long isoform modulates malignancy of poorly differentiated colon cancer cells. Gut 65, 821-829, doi:10.1136/gutjnl-2014-308781 (2016).

69           Bachelet, T. et al. Deleterious impact of donor-specific Anti-HLA antibodies toward HLA-Cw and HLA-DP in kidney transplantation. Transplantation 100, 159-166, doi:10.1097/TP.0000000000000821 (2016).

70           Bachelet, T., Merville, P., Dechanet-Merville, J. & Couzi, L. Cytomegalovirus-induced γδ T cells during rejection: An ambivalent T cell. American Journal of Transplantation 16, 368-369, doi:10.1111/ajt.13568 (2016).

71           Bachelet, T. et al. Anti-HLA donor-specific antibodies are not created equally. Don’t forget the flow. Transplant International 29, 508-510, doi:10.1111/tri.12745 (2016).

72           Bannwarth, B., Truchetet, M. E. & Kostine, M. Gastrointestinal tract and anti-inflammatory drugs (NSAIDs, corticosteroids). Revue du Rhumatisme Monographies 83, 245-248, doi:10.1016/j.monrhu.2016.03.007 (2016).

73           Baulier, G., Victor, J., Mercié, P., Lazaro, E. & Duffau, P. Cough as the presenting feature of pulmonary AL amyloidosis: A case report. Revue de Medecine Interne 37, 363-366, doi:10.1016/j.revmed.2015.08.008 (2016).

74           Bentebibel, S. E. et al. ICOS + PD-1 + CXCR3 + T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination. Scientific Reports 6, doi:10.1038/srep26494 (2016).

75           Berge, J. et al. Understanding flow patterns and inflammatory status in intracranial aneurysms: Towards a personalized medicine. Journal of Neuroradiology 43, 141-147, doi:10.1016/j.neurad.2015.09.005 (2016).

76           Billat, P. A. et al. Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. Pharmacological Research 111, 501-508, doi:10.1016/j.phrs.2016.07.012 (2016).

77           Bitoun, S. et al. Study of two predisposing polymorphisms associated with multiple sclerosis in patients with demyelinating complications related to anti-TNF alpha therapy. Revue du Rhumatisme (Edition Francaise) 83, A70-A71, doi:10.1016/S1169-8330(16)30265-4 (2016).

78           Blanchi, J., Goret, J. & Mégraud, F. Clostridium difficile Infection: A Model for Disruption of the Gut Microbiota Equilibrium. Digestive Diseases 34, 217-220, doi:10.1159/000443355 (2016).

79           Blanco, P., Ueno, H. & Schmitt, N. T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis. European Journal of Immunology 46, 281-290, doi:10.1002/eji.201545760 (2016).

80           Bommarito, D. et al. Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway. Cancer Immunology, Immunotherapy 65, 355-366, doi:10.1007/s00262-016-1804-y (2016).

81           Bonnet, F. et al. VIH-25 – Evolution of patient characteristics and comorbidities in a cohort of people living with HIV, 2004-2014. Medecine et Maladies Infectieuses 46, 126, doi:10.1016/S0399-077X(16)30570-4 (2016).

82           Brembilla, N. C. et al. IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. Annals of the Rheumatic Diseases 75, 1697-1705, doi:10.1136/annrheumdis-2015-207477 (2016).

83           Collin, A. et al. Incidence and risk factors for Severe bacterial infections in people living with HIV. ANRS CO3 Aquitaine cohort, 2000-2012. PLoS ONE 11, doi:10.1371/journal.pone.0152970 (2016).

84           Contis, A. et al. Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review. Clinical Rheumatology 35, 517-522, doi:10.1007/s10067-015-3166-9 (2016).

85           Crickx, E. et al. Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A French Nationwide Study of Ninety-Two Patients. Arthritis and Rheumatology 68, 702-712, doi:10.1002/art.39472 (2016).

86           Cunin, P. et al. Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses. Cell Death and Disease 7, doi:10.1038/cddis.2016.113 (2016).

87           Dagenais, M. et al. A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways. Mucosal Immunology 9, 146-158, doi:10.1038/mi.2015.46 (2016).

88           Dagenais, M. & Saleh, M. Linking cancer-induced Nlrp3 inflammasome activation to efficient NK cell-mediated immunosurveillance. OncoImmunology 5, doi:10.1080/2162402X.2015.1129484 (2016).

89           Darrigade, A. S. et al. Pigmented skin patches without scleroderma as a predominant clinical symptom revealing systemic sclerosis. Clinical and Experimental Dermatology 41, 379-382, doi:10.1111/ced.12752 (2016).

90           Daste, A. et al. Targeted therapy and elderly people: A review. European Journal of Cancer 69, 199-215, doi:10.1016/j.ejca.2016.10.005 (2016).

91           Dezutter-Dambuyant, C. et al. A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. OncoImmunology 5, doi:10.1080/2162402X.2015.1091146 (2016).

92           Ducreux, J. et al. Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: Analysis of extended follow-up data from the interferon α kinoid phase I/II study. Rheumatology (United Kingdom) 55, 1901-1905, doi:10.1093/rheumatology/kew262 (2016).

93           Dufour, N. et al. Bacteriophage LM33_P1, a fast-acting weapon against the pandemic ST131-O25b: H4 Escherichia coli clonal complex. Journal of Antimicrobial Chemotherapy 71, 3072-3080, doi:10.1093/jac/dkw253 (2016).

94           Durel, C. A. et al. Observational study of a French and Belgian multicenter cohort of 23 patients diagnosed in adulthood with mevalonate kinase deficiency. Medicine (United States) 95, doi:10.1097/MD.0000000000003027 (2016).

95           Duron, L. et al. Shrinking lung syndrome associated with systemic lupus erythematosus: A multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. Autoimmunity Reviews 15, 994-1000, doi:10.1016/j.autrev.2016.07.021 (2016).

96           Faguer, S. et al. Calcineurin inhibitors downregulate hnf-1b and may affect the outcome of HNF1B patients after renal transplantation. Transplantation 100, 1970-1978, doi:10.1097/TP.0000000000000993 (2016).

97           Fessart, D. et al. Secretion of protein disulphide isomerase AGR2 confers tumorigenic properties. eLife 5, doi:10.7554/eLife.13887 (2016).

98           Forcade, E. et al. Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood 127, 2489-2497, doi:10.1182/blood-2015-12-688895 (2016).

99           Fumery, M. et al. Natural History of Crohn’s Disease in Elderly Patients Diagnosed over the Age of 70 Years: A Population-Based Study. Inflammatory Bowel Diseases 22, 1698-1707, doi:10.1097/MIB.0000000000000821 (2016).

100         Garcia-Beltran, W. F. et al. Open conformers of HLA-F are high-affinity ligands of the activating NK-cell receptor KIR3DS1. Nature Immunology 17, 1067-1074, doi:10.1038/ni.3513 (2016).

101         Garrigue, I. et al. Contribution of next generation sequencing to early detection of cytomegalovirus UL97 emerging mutants and viral subpopulations analysis in kidney transplant recipients. Journal of Clinical Virology 80, 74-81, doi:10.1016/j.jcv.2016.04.017 (2016).

102         Gensous, N., Turpin, D., Duluc, D., Contin-Bordes, C. & Blanco, P. Genèse des anticorps. Revue du Rhumatisme (Edition Francaise) 83, A27-A32, doi:10.1016/S1169-8330(16)30201-0 (2016).

103         Goret, J. et al. Surface lipoproteome of Mycoplasma hominis PG21 and differential expression after contact with human dendritic cells. Future Microbiology 11, 179-194, doi:10.2217/fmb.15.130 (2016).

104         Gossec, L. et al. Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France. Joint Bone Spine 83, 501-509, doi:10.1016/j.jbspin.2016.05.012 (2016).

105         Gottenberg, J. E. et al. NonTNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: A randomized clinical trial. JAMA – Journal of the American Medical Association 316, 1172-1180, doi:10.1001/jama.2016.13512 (2016).

106         Grenier, N., Merville, P. & Combe, C. Radiologic imaging of the renal parenchyma structure and function. Nature Reviews Nephrology 12, 348-359, doi:10.1038/nrneph.2016.44 (2016).

107         Guidicelli, G. et al. Non-complement-binDing de novo donor-specific anti-HLA antibodies and kidney allograft survival. Journal of the American Society of Nephrology 27, 615-625, doi:10.1681/ASN.2014040326 (2016).

108         Jacquemin, C. & Blanco, P. The Role of Dendritic Cells in Systemic Lupus Erythematosus. Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects, 131-136, doi:10.1016/B978-0-12-801917-7.00016-4 (2016).

109         Juge, P. A. et al. Fond génétique partagé entre la pneumopathie interstitielle diffuse associée à la polyarthrite rhumatoïde et la fibrose pulmonaire idiopathique. Revue du Rhumatisme (Edition Francaise) 83, A91-A92, doi:10.1016/S1169-8330(16)30345-3 (2016).

110         Juge, P. A. et al. Identification de marqueurs associés à la présence d’une pneumopathie interstitielle diffuse chez les patients atteints d’une polyarthrite rhumatoïde. Revue du Rhumatisme (Edition Francaise) 83, A92, doi:10.1016/S1169-8330(16)30346-5 (2016).

111         Juge, P. A. et al. Pneumopathie interstitielle diffuse associée à la polyarthrite rhumatoïde : étude descriptive de 189 patients provenant de la cohorte française TRANSLATE. Revue du Rhumatisme (Edition Francaise) 83, A128-A129, doi:10.1016/S1169-8330(16)30405-7 (2016).

112         Kaminski, H. et al. Easier Control of Late-Onset Cytomegalovirus Disease Following Universal Prophylaxis Through an Early Antiviral Immune Response in Donor-Positive, Recipient-Negative Kidney Transplants. American Journal of Transplantation 16, 2384-2394, doi:10.1111/ajt.13781 (2016).

113         Kaminski, H. & Fishman, J. A. The Cell Biology of Cytomegalovirus: Implications for Transplantation. American Journal of Transplantation 16, 2254-2269, doi:10.1111/ajt.13791 (2016).

114         Kaminski, H. et al. Surveillance of gd T cells predicts cytomegalovirus infection resolution in kidney transplants. Journal of the American Society of Nephrology 27, 637-645, doi:10.1681/ASN.2014100985 (2016).

115         Khoryati, L. et al. IgE Inhibits Toll-like Receptor 7– and Toll-like Receptor 9–Mediated Expression of Interferon-α by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology 68, 2221-2231, doi:10.1002/art.39679 (2016).

116         Kleinmann, J. F. et al. French-speaking, international and multidisciplinary expert recommendations for the use of biomedicines in systemic lupus erythematosus: The CRI-IMIDIATE working group. Revue du Rhumatisme (Edition Francaise) 83, A40, doi:10.1016/S1169-8330(16)30211-3 (2016).

117         Kostine, M., Lichtwitz, O., Truchetet, M. E. & Leveziel, N. Ostéome choroïdien : de l’os dans l’œil. Revue du Rhumatisme (Edition Francaise) 83, 310, doi:10.1016/j.rhum.2016.05.001 (2016).

118         Kostine, M., Lichtwitz, O., Truchetet, M. E. & Leveziel, N. Choroidal osteoma: Bone in the eye. Joint Bone Spine 83, 454, doi:10.1016/j.jbspin.2015.07.005 (2016).

119         Lemoine, M. Molecular Complexity: Why has psychiatry not been revolutionized by genomics (Yet)? Philosophy of Molecular Medicine: Foundational Issues in Research and Practice, 81-99, doi:10.4324/9781315674162 (2016).

120         Leroy, V. et al. Successful rapid subcutaneous desensitization to anakinra in a case of delayed-type hypersensitivity reaction. British Journal of Dermatology 174, 1417-1418, doi:10.1111/bjd.14454 (2016).

121         Loiseau, P. et al. Use of Single-Antigen Flow Beads Assays to Assess Anti-HLA Donor-Specific Antibody Strength. Biology of Blood and Marrow Transplantation 22, 394-395, doi:10.1016/j.bbmt.2015.11.006 (2016).

122         Moreau, J. F., Guindon, F. & Langevin, E. The northern route, between the Saguenay and Georgian Bay: Construction of a hypothesis. Contact in the 16Th Century: Networks among Fishers, Foragers and Farmers, 171-197 (2016).

123         Moro-Sibilot, L. et al. Plasmacytoid dendritic cells are dispensable for noninfectious intestinal IgA responses in vivo. European Journal of Immunology 46, 354-359, doi:10.1002/eji.201545977 (2016).

124         Pereyre, S., Goret, J. & Bébéar, C. Mycoplasma pneumoniae: Current knowledge on macrolide resistance and treatment. Frontiers in Microbiology 7, doi:10.3389/fmicb.2016.00974 (2016).

125         Poissonnier, A. et al. CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice. Immunity 45, 209-223, doi:10.1016/j.immuni.2016.06.028 (2016).

126         Pouché, L. et al. A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation. Pharmacogenomics 17, 375-391, doi:10.2217/pgs.15.181 (2016).

127         Pouplin, S. et al. Development of a “comorbidities” self-questionnaire for patients with chronic inflammatory rheumatism: A project from the 2015 Rheumatology Experts Meeting. Revue du Rhumatisme (Edition Francaise) 83, A89-A90, doi:10.1016/S1169-8330(16)30342-8 (2016).

128         Pradeu, T. The many faces of biological individuality. Biology and Philosophy 31, 761-773, doi:10.1007/s10539-016-9553-z (2016).

129         Pradeu, T. Organisms or biological individuals? Combining physiological and evolutionary individuality. Biology and Philosophy 31, 797-817, doi:10.1007/s10539-016-9551-1 (2016).

130         Pradeu, T. Mutualistic viruses and the heteronomy of life. Studies in History and Philosophy of Science Part C :Studies in History and Philosophy of Biological and Biomedical Sciences 59, 80-88, doi:10.1016/j.shpsc.2016.02.007 (2016).

131         Pradeu, T. Toolbox murders: putting genes in their epigenetic and ecological contexts: P. Griffiths and K. Stotz: Genetics and philosophy: an introduction. Biology and Philosophy 31, 125-142, doi:10.1007/s10539-014-9471-x (2016).

132         Pradeu, T., Kostyrka, G. & Dupré, J. Understanding viruses: Philosophical investigations. Studies in History and Philosophy of Science Part C :Studies in History and Philosophy of Biological and Biomedical Sciences 59, 57-63, doi:10.1016/j.shpsc.2016.02.008 (2016).

133         Pradeu, T. et al. Defining “Development”. Current Topics in Developmental Biology 117, 171-183, doi:10.1016/bs.ctdb.2015.10.012 (2016).

134         Pradeu, T. & Vivier, E. The discontinuity theory of immunity. Science Immunology 1, doi:10.1126/sciimmunol.aag0479 (2016).

135         Pugès, M. et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: A systematic literature review and meta-analysis. Rheumatology (United Kingdom) 55, 1664-1672, doi:10.1093/rheumatology/kew211 (2016).

136         Rey, C. et al. The MAP3K ZAK, a novel modulator of ERK-dependent migration, is upregulated in colorectal cancer. Oncogene 35, 3190-3200, doi:10.1038/onc.2015.379 (2016).

137         Sautenet, B. et al. One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation 100, 391-399, doi:10.1097/TP.0000000000000958 (2016).

138         Scherlinger, M., Claire, C., Barnetche, T., Lazaro, E. & Richez, C. EXPLORER: A new perspective on old data. Revue du Rhumatisme (Edition Francaise) 83, A106-A107, doi:10.1016/S1169-8330(16)30368-4 (2016).

139         Scherlinger, M. et al. Étude d’efficacité et tolérance de la substitution de l’infliximab princeps par le biosimilaire Inflectra® : résultats issus d’une cohorte prospective de patients atteints de polyarthrite rhumatoïde et de spondyloarthrite au CHU de Bordeaux. Revue du Rhumatisme (Edition Francaise) 83, A99-A100, doi:10.1016/S1169-8330(16)30357-X (2016).

140         Schmitt, N., Liu, Y., Bentebibel, S. E. & Ueno, H. Molecular Mechanisms Regulating T Helper 1 versus T Follicular Helper Cell Differentiation in Humans. Cell Reports 16, 1082-1095, doi:10.1016/j.celrep.2016.06.063 (2016).

141         Servais, A. et al. Atypical haemolytic uraemic syndrome and pregnancy: Outcome with ongoing eculizumab. Nephrology Dialysis Transplantation 31, 2122-2130, doi:10.1093/ndt/gfw314 (2016).

142         Sisirak, V. et al. Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. Cell 166, 88-101, doi:10.1016/j.cell.2016.05.034 (2016).

143         Skeldon, A. M. et al. Caspase-12, but not caspase-11, inhibits obesity and insulin resistance. Journal of Immunology 196, 437-447, doi:10.4049/jimmunol.1501529 (2016).

144         Stokes, J., Hoffman, E. A., Zeng, Y., Larmonier, N. & Katsanis, E. Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation. British Journal of Haematology 174, 102-116, doi:10.1111/bjh.14034 (2016).

145         Thibault, G. et al. CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen. Transplant International 29, 184-195, doi:10.1111/tri.12688 (2016).

146         Truchetet, M. E. et al. Platelets Induce Thymic Stromal Lymphopoietin Production by Endothelial Cells: Contribution to Fibrosis in Human Systemic Sclerosis. Arthritis and Rheumatology 68, 2784-2794, doi:10.1002/art.39817 (2016).

147         Truchetet, M. E. et al. Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: Data from the ORA registry. Arthritis Research and Therapy 18, doi:10.1186/s13075-016-0956-7 (2016).

148         Turpin, D. et al. Role of extracellular vesicles in autoimmune diseases. Autoimmunity Reviews 15, 174-183, doi:10.1016/j.autrev.2015.11.004 (2016).

149         Vergne-Salle, P. et al. Évaluation multidimensionnelle de la douleur dans la polyarthrite rhumatoïde. Revue du Rhumatisme (Edition Francaise) 83, A127, doi:10.1016/S1169-8330(16)30403-3 (2016).

150         Villeneuve, C. et al. Evolution and determinants of health-related quality-of-life in kidney transplant patients over the first 3 years after transplantation. Transplantation 100, 640-647, doi:10.1097/TP.0000000000000846 (2016).

151         Visentin, J. et al. Lung intragraft donor-specific antibodies as a risk factor for graft loss. Journal of Heart and Lung Transplantation 35, 1418-1426, doi:10.1016/j.healun.2016.06.010 (2016).

152         Visentin, J. et al. Deciphering IgM interference in IgG anti-HLA antibody detection with flow beads assays. Human Immunology 77, 1048-1054, doi:10.1016/j.humimm.2016.02.008 (2016).

153         Visentin, J., Guidicelli, G. & Taupin, J. L. Are complement-fixing antibodies against denatured HLA antigens clinically relevant? Experimental and Molecular Pathology 100, 532-533, doi:10.1016/j.yexmp.2016.01.008 (2016).

154         Visentin, J., Minder, L., Lee, J. H., Taupin, J. L. & Di Primo, C. Calibration free concentration analysis by surface plasmon resonance in a capture mode. Talanta 148, 478-485, doi:10.1016/j.talanta.2015.11.025 (2016).

155         Visentin, J., Ramaharo, D., Ryman, A., Contin-Bordes, C. & Merville, P. Prevalence of IgA antibodies to b2-glycoprotein I: A population-dependent feature? Transplantation 100, e13-e14, doi:10.1097/TP.0000000000001062 (2016).

156         Wislez, M., Domblides, C., Cortot, A. & Lemoine, A. Mutations at the splice sites of exon 14 of MET gene: A new target for sarcomatoid carcinomas? Annals of Translational Medicine 4, doi:10.21037/atm.2016.01.12 (2016).

157         Yin, W. et al. Therapeutic HPV cancer vaccine targeted to CD40 elicits effective CD8+ T-cell immunity. Cancer Immunology Research 4, 823-834, doi:10.1158/2326-6066.CIR-16-0128 (2016).

158         Yin, W. et al. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8 + and CD4 + T Cells. EBioMedicine 5, 46-58, doi:10.1016/j.ebiom.2016.01.029 (2016).

159         Zaidan, M. et al. Spectrum and prognosis of noninfectious renal mixed cryoglobulinemic GN. Journal of the American Society of Nephrology 27, 1213-1224, doi:10.1681/ASN.2015020114 (2016).